Accuray (ARAY) 10-Q 8 May 24 2024 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Mar. 31, 2024	May 01, 2024
Cover [Abstract]
Entity Registrant Name	ACCURAY INCORPORATED
Entity Central Index Key	0001138723
Document Type	10-Q
Document Period End Date	Mar. 31, 2024
Amendment Flag	false
Current Fiscal Year End Date	--06-30
Entity Current Reporting Status	Yes
Trading Symbol	ARAY
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		99,244,173
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q3
Entity File Number	001-33301
Entity Tax Identification Number	20-8370041
Entity Address, Address Line One	1240 Deming Way
Entity Address, City or Town	Madison
Entity Address, State or Province	WI
Entity Address, Postal Zip Code	53717
City Area Code	608
Local Phone Number	824-2800
Entity Incorporation, State or Country Code	DE
Entity Interactive Data Current	Yes
Document Quarterly Report	true
Document Transition Report	false
Title of 12(b) Security	Common Stock, $0.001 par value per share
Security Exchange Name	NASDAQ

Unaudited Condensed Consolidate

Unaudited Condensed Consolidated Balance Sheets - USD ($) $ in Thousands		Mar. 31, 2024	Jun. 30, 2023
Current assets:
Cash and cash equivalents		$ 60,450	$ 89,402
Restricted cash		674	524
Accounts receivable, net of allowance for credit losses of $2,791 and $3,079 as of March 31, 2024, and June 30, 2023, respectively	[1]	73,154	74,777
Inventories		159,566	145,150
Prepaid expenses and other current assets	[2]	19,043	27,612
Deferred cost of revenue		1,023	568
Total current assets		313,910	338,033
Property and equipment, net		25,387	20,926
Investment in joint venture		13,586	15,128
Operating lease right-of-use assets, net		29,127	25,853
Goodwill		57,682	57,681
Intangible assets, net		70	210
Restricted cash		1,030	1,276
Other assets		21,735	20,107
Total assets		462,527	479,214
Current liabilities:
Accounts payable		44,430	33,739
Accrued compensation		21,604	23,793
Operating lease liabilities, current		5,279	4,151
Other accrued liabilities		30,703	38,271
Customer advances		15,392	20,777
Deferred revenue		73,734	72,185
Short-term debt		7,248	5,721
Total current liabilities		198,390	198,637
Long-term liabilities:
Operating lease liabilities, non-current		28,217	23,602
Long-term other liabilities		4,969	4,675
Deferred revenue, non-current		23,624	27,079
Long-term debt		166,246	171,562
Total liabilities		421,446	425,555
Commitments and contingencies (Note 8)
Stockholders' equity:
Common stock, $0.001 par value; authorized: 200,000,000 shares as of March 31, 2024, and June 30, 2023, respectively; issued and outstanding: 99,244,173 and 96,534,609 shares at March 31, 2024, and June 30, 2023, respectively		99	97
Additional paid-in-capital		563,958	555,276
Accumulated other comprehensive income (loss)		(1,908)	422
Accumulated deficit		(521,068)	(502,136)
Total stockholders' equity		41,081	53,659
Total liabilities and stockholders' equity		$ 462,527	$ 479,214
[1] Includes accounts receivable from the joint venture, an equity method invest ment, of $ 17,563 and $ 10,304 at March 31, 2024, and June 30, 2023 , respectively. See Note 13. Includes other receivables from the joint venture, an equity method investment, of $ 100 at June 30, 2023 . There were no other receivables from the joint venture at March 31, 2024.

Unaudited Condensed Consolida_2

Unaudited Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2024	Jun. 30, 2023
Accounts receivable, allowance for credit losses (in dollars)	$ 2,791	$ 3,079
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized shares	200,000,000	200,000,000
Common stock, issued shares	99,244,173	96,534,609
Common stock, outstanding shares	99,244,173	96,534,609
Accounts Receivable | Corporate Joint Venture
Accounts receivable from joint venture	$ 17,563	$ 10,304
Prepaid Expenses and Other Current Assets | Corporate Joint Venture
Accounts receivable from joint venture	$ 0	$ 100

Unaudited Condensed Consolida_3

Unaudited Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($) shares in Thousands, $ in Thousands		3 Months Ended		9 Months Ended
		Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Net revenue:
Total net revenue		$ 101,132	$ 118,060	$ 312,262	$ 329,313
Cost of revenue:
Total cost of revenue	[1]	72,058	79,342	207,793	213,031
Gross profit		29,074	38,718	104,469	116,282
Operating expenses:
Research and development	[2]	10,909	14,209	40,203	42,942
Selling and marketing		10,318	11,130	31,923	35,511
General and administrative		12,409	11,063	38,656	34,990
Total operating expenses		33,636	36,402	110,782	113,443
Income (loss) from operations		(4,562)	2,316	(6,313)	2,839
Income from equity method investment, net		1,024	2,027	1,028	960
Other expense, net		(2,360)	(3,222)	(10,393)	(8,611)
Income (loss) before provision for income taxes		(5,898)	1,121	(15,678)	(4,812)
Provision for income taxes		444	522	3,254	1,912
Net income (loss)		$ (6,342)	$ 599	$ (18,932)	$ (6,724)
Net income (loss) per share - basic		$ (0.06)	$ 0.01	$ (0.19)	$ (0.07)
Net income (loss) per share - diluted		$ (0.06)	$ 0.01	$ (0.19)	$ (0.07)
Weighted average common shares used in computing net income (loss) per share:
Basic		99,197	95,522	97,838	94,532
Diluted		99,197	97,455	97,838	94,532
Other comprehensive income (loss):
Net Income (Loss)		$ (6,342)	$ 599	$ (18,932)	$ (6,724)
Foreign currency translation adjustment		(2,965)	801	(2,330)	(64)
Comprehensive income (loss)		(9,307)	1,400	(21,262)	(6,788)
Products
Net revenue:
Total net revenue	[3]	49,603	62,846	154,491	170,738
Cost of revenue:
Total cost of revenue		35,945	43,529	105,977	111,627
Services
Net revenue:
Total net revenue	[4]	51,529	55,214	157,771	158,575
Cost of revenue:
Total cost of revenue		$ 36,113	$ 35,813	$ 101,816	$ 101,404
[1] Includes cost of revenue from sales to the joint venture, an equity method investment, of $ 13,887 and $ 40,260 during the three and nine months ended March 31, 2024 and $ 13,905 and $ 29,728 during the three and nine months ended March 31, 2023, respectively . Includes charge backs to the joint venture, an equity method investment, related to research and development of $ 199 during the nine months ended March 31, 2024, and $ 97 and $ 1,363 during the three and nine months ended March 31, 2023 , respectively. There were no charge backs to the joint venture related to research and development during the three months ended March 31, 2024. Includes sales of products to the joint venture, an equity method investment, of $ 15,662 and $ 55,504 during the three and nine months ended March 31, 2024 and $ 18,118 and $ 43,702 during the three and nine months ended March 31, 2023 , respectively. See Note 13. Includes sales of services to the joint venture, an equity method investment, of $ 3,982 and $ 10,970 during the three and nine months ended March 31, 2024 and $ 2,696 and $ 8,147 during the three and nine months ended March 31, 2023 , respectively. See Note 13.

Unaudited Condensed Consolida_4

Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Total net revenue		$ 101,132	$ 118,060	$ 312,262	$ 329,313
Total cost of revenue	[1]	72,058	79,342	207,793	213,031
Research and development	[2]	10,909	14,209	40,203	42,942
Products
Total net revenue	[3]	49,603	62,846	154,491	170,738
Total cost of revenue		35,945	43,529	105,977	111,627
Services
Total net revenue	[4]	51,529	55,214	157,771	158,575
Total cost of revenue		36,113	35,813	101,816	101,404
Revenue from Joint Venture
Total cost of revenue		13,887	13,905	40,260	29,728
Research and development		0	97	199	1,363
Revenue from Joint Venture | Products
Total net revenue		15,662	18,118	55,504	43,702
Revenue from Joint Venture | Services
Total net revenue		$ 3,982	$ 2,696	$ 10,970	$ 8,147
[1] Includes cost of revenue from sales to the joint venture, an equity method investment, of $ 13,887 and $ 40,260 during the three and nine months ended March 31, 2024 and $ 13,905 and $ 29,728 during the three and nine months ended March 31, 2023, respectively . Includes charge backs to the joint venture, an equity method investment, related to research and development of $ 199 during the nine months ended March 31, 2024, and $ 97 and $ 1,363 during the three and nine months ended March 31, 2023 , respectively. There were no charge backs to the joint venture related to research and development during the three months ended March 31, 2024. Includes sales of products to the joint venture, an equity method investment, of $ 15,662 and $ 55,504 during the three and nine months ended March 31, 2024 and $ 18,118 and $ 43,702 during the three and nine months ended March 31, 2023 , respectively. See Note 13. Includes sales of services to the joint venture, an equity method investment, of $ 3,982 and $ 10,970 during the three and nine months ended March 31, 2024 and $ 2,696 and $ 8,147 during the three and nine months ended March 31, 2023 , respectively. See Note 13.

Unaudited Condensed Consolida_5

Unaudited Condensed Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Balance at Jun. 30, 2022	$ 53,189	$ 94	$ 543,211	$ 2,406	$ (492,522)
Balance (in shares) at Jun. 30, 2022		93,500,000
Issuance of common stock to employees, (In shares)		279,000
Share-based compensation	2,906		2,906
Net Income (Loss)	(5,449)				(5,449)
Foreign currency translation adjustment	(3,655)			(3,655)
Balance at Sep. 30, 2022	46,991	$ 94	546,117	(1,249)	(497,971)
Balance (in shares) at Sep. 30, 2022		93,779,000
Balance at Jun. 30, 2022	53,189	$ 94	543,211	2,406	(492,522)
Balance (in shares) at Jun. 30, 2022		93,500,000
Net Income (Loss)	(6,724)
Foreign currency translation adjustment	(64)
Balance at Mar. 31, 2023	54,705	$ 96	551,847	2,342	(499,580)
Balance (in shares) at Mar. 31, 2023		95,558,000
Balance at Sep. 30, 2022	46,991	$ 94	546,117	(1,249)	(497,971)
Balance (in shares) at Sep. 30, 2022		93,779,000
Issuance of common stock to employees	1,139	$ 1	1,138
Issuance of common stock to employees, (In shares)		1,765,000
Tax withholding upon vesting of restricted stock units	(116)		(116)
Tax withholding upon vesting of restricted stock units (in shares)		(50,000)
Share-based compensation	3,136		3,136
Net Income (Loss)	(1,874)				(1,874)
Foreign currency translation adjustment	2,790			2,790
Other	(321)		13		(334)
Balance at Dec. 31, 2022	51,745	$ 95	550,288	1,541	(500,179)
Balance (in shares) at Dec. 31, 2022		95,494,000
Issuance of common stock to employees	1	$ 1
Issuance of common stock to employees, (In shares)		64,000
Share-based compensation	1,559		1,559
Net Income (Loss)	599				599
Foreign currency translation adjustment	801			801
Balance at Mar. 31, 2023	54,705	$ 96	551,847	2,342	(499,580)
Balance (in shares) at Mar. 31, 2023		95,558,000
Balance at Dec. 31, 2023	47,653	$ 99	561,223	1,057	(514,726)
Balance (in shares) at Dec. 31, 2023		99,164,000
Balance at Jun. 30, 2023	$ 53,659	$ 97	555,276	422	(502,136)
Balance (in shares) at Jun. 30, 2023	96,534,609	96,535,000
Issuance of common stock to employees, (In shares)		192,000
Share-based compensation	$ 2,392		2,392
Net Income (Loss)	(2,969)				(2,969)
Foreign currency translation adjustment	(2,138)			(2,138)
Balance at Sep. 30, 2023	50,944	$ 97	557,668	(1,716)	(505,105)
Balance (in shares) at Sep. 30, 2023		96,727,000
Balance at Jun. 30, 2023	$ 53,659	$ 97	555,276	422	(502,136)
Balance (in shares) at Jun. 30, 2023	96,534,609	96,535,000
Net Income (Loss)	$ (18,932)
Foreign currency translation adjustment	(2,330)
Balance at Mar. 31, 2024	$ 41,081	$ 99	563,958	(1,908)	(521,068)
Balance (in shares) at Mar. 31, 2024	99,244,173	99,244,000
Balance at Sep. 30, 2023	$ 50,944	$ 97	557,668	(1,716)	(505,105)
Balance (in shares) at Sep. 30, 2023		96,727,000
Issuance of common stock to employees	1,360	$ 2	1,358
Issuance of common stock to employees, (In shares)		2,484,000
Tax withholding upon vesting of restricted stock units	(117)		(117)
Tax withholding upon vesting of restricted stock units (in shares)		(47,000)
Share-based compensation	2,314		2,314
Net Income (Loss)	(9,621)				(9,621)
Foreign currency translation adjustment	2,773			2,773
Balance at Dec. 31, 2023	47,653	$ 99	561,223	1,057	(514,726)
Balance (in shares) at Dec. 31, 2023		99,164,000
Issuance of common stock to employees, (In shares)		80,000
Share-based compensation	2,735		2,735
Net Income (Loss)	(6,342)				(6,342)
Foreign currency translation adjustment	(2,965)			(2,965)
Balance at Mar. 31, 2024	$ 41,081	$ 99	$ 563,958	$ (1,908)	$ (521,068)
Balance (in shares) at Mar. 31, 2024	99,244,173	99,244,000

Unaudited Condensed Consolida_6

Unaudited Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash flows from operating activities
Net loss	$ (18,932)	$ (6,724)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	4,398	3,430
Share-based compensation	7,441	7,601
Amortization of debt issuance costs	711	688
Recovery from credit losses	(145)	(410)
Provision for write-down of inventories	3,682	2,565
Loss on disposal of property and equipment	5	55
Income from equity method investment	(1,028)	(960)
Net revenue deferred from intra-entity profit margin from sales	2,156	1,333
Changes in assets and liabilities:
Accounts receivable	1,869	18,970
Inventories	(22,667)	(9,530)
Prepaid expenses and other assets	4,426	(5,946)
Deferred cost of revenue	(446)	1,176
Accounts payable	11,979	(2,008)
Operating lease liabilities, net of operating lease right-of-use assets	(123)	(153)
Accrued compensation and accrued liabilities	(8,931)	(623)
Customer advances	(5,296)	(3,391)
Deferred revenues	(885)	585
Net cash provided by (used in) operating activities	(21,786)	6,658
Cash flows from investing activities
Purchases of property and equipment	(3,136)	(4,579)
Acquisition of assets	0	(59)
Purchase of intangible asset	0	(67)
Net cash used in investing activities	(3,136)	(4,705)
Cash flows from financing activities
Proceeds from the issuance of common stock to employees	1,360	1,139
Taxes paid related to net share settlement of equity awards	(117)	(116)
Debt issuance costs	0	(248)
Paydown under Term Loan Facility	(4,500)	(4,500)
Repayments of convertible notes	0	(2,865)
Borrowings under Revolving Credit Facility	0	5,000
Net cash used in financing activities	(3,257)	(1,590)
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(869)	333
Net increase (decrease) in cash, cash equivalents and restricted cash	(29,048)	696
Cash, cash equivalents and restricted cash at beginning of period	91,202	90,154
Cash, cash equivalents and restricted cash at end of period	62,154	90,850
Supplemental non-cash disclosure:
Transfers from inventory to property and equipment, net	3,285	0
Leasehold improvement from lease incentive	2,593	0
Unpaid purchase of property and equipment and end of period	$ 174	$ 104

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Mar. 31, 2024	Dec. 31, 2023	Sep. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Mar. 31, 2024	Mar. 31, 2023
Pay vs Performance Disclosure
Net Income (Loss)	$ (6,342)	$ (9,621)	$ (2,969)	$ 599	$ (1,874)	$ (5,449)	$ (18,932)	$ (6,724)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Mar. 31, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

The Company and its Significant

The Company and its Significant Accounting Policies	9 Months Ended
	Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
The Company and its Significant Accounting Policies	Note 1. The Company and its Significant Accounting Policies The Company Accuray Incorporated (together with its subsidiaries, the “Company” or “Accuray”) designs, develops and sells advanced radiosurgery and radiation therapy systems for the treatment of tumors throughout the body. The Company is incorporated in Delaware and its headquarters are located in Madison, Wisconsin. The Company has primary offices in the United States, Switzerland, China, Hong Kong, and Japan, and conducts its business worldwide. Basis of Presentation The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany transactions and balances have been eliminated in consolidation. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”), pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information and note disclosures have been condensed or omitted pursuant to such rules and regulations. The unaudited condensed consolidated financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair presentation of the periods presented. The results for the three and nine months ended March 31, 2024 are not necessarily indicative of the results to be expected for the fiscal year ending June 30, 2024, or for any other future interim period or fiscal year. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and accompanying notes for the fiscal year ended June 30, 2023 included in the Company’s Annual Report on Form 10-K filed with the SEC on September 7, 2023. Reclassifications Certain amounts on the unaudited condensed consolidated statements of cash flows and statements of stockholders' equity in prior periods have been reclassified to conform to current year presentation. Risks and Uncertainties The Company is subject to risks and uncertainties caused, directly or indirectly, by events with significant geopolitical and macroeconomic impacts, including, but not limited to, rising inflation; actions taken to counter inflation, including rising interest rates; foreign currency exchange rate fluctuations; uncertainty and volatility in the banking and financial services sector; tightening credit markets; the effects of the COVID-19 pandemic; geopolitical concerns, such as the Russia-Ukraine and Israel-Hamas conflicts and increasing tension between China and the U.S., including with respect to Taiwan; and other factors that may emerge. In particular, the Company is also continuing to navigate supply chain and inflation challenges, and adverse foreign currency exchange rate fluctuations, all of which continues to be a significant headwind that affects the Company’s results of operations. The Company expects that the business of its customers and its own business will continue to be adversely impacted, directly or indirectly, by these macroeconomic and geopolitical issues. Delays in deliveries and installations as a result of the COVID-19 pandemic and its effects on the global economic environment may continue, to some degree, through the remainder of calendar year 2024, which could have a negative impact on our revenue during such period. In addition, ongoing supply chain challenges and logistics costs, including difficulties in obtaining a sufficient supply of component materials and increased component costs, have adversely affected the Company's gross margins and net income (loss), and the Company’s current expectations are that gross margins and net income (loss) will continue to be adversely affected by increased material costs and freight and logistic expenses through at least the remainder of calendar year 2024, if not longer. In addition, reduced budgets and lower capital deployment priority for radiotherapy equipment, along with longer customer installation timelines, in the United States have negatively impacted our revenue during the third quarter of fiscal 2024, which we expect will continue to have an impact through at least fiscal year 2026. Furthermore, certain parts required for the manufacturing and servicing of the Company's products, such as electronic components, are scarce and could be difficult to source, even at increased prices, if the supplier were adversely affected by macroeconomic and geopolitical issues. If such parts become unavailable to the Company, it would not be able to manufacture or service our products, which would adversely impact revenue, gross margins, and net income (loss). The extent of the ongoing impact of these macroeconomic events on our business, our markets and on global economic activity, however, is uncertain and the related financial impact cannot be reasonably estimated with any certainty at this time. The Company’s past results may not be indicative of its future performance, and historical trends, including conversion of backlog to revenue, income (loss) from operations, net income (loss), net income (loss) per share and cash flows may differ materially. The Company continues to critically review its liquidity and anticipated capital requirements in light of the significant uncertainty created by geopolitical and macroeconomic conditions. Based on the Company’s cash and cash equivalents balance, available debt facilities, current business plan and revenue prospects, the Company believes that it will have sufficient cash resources and anticipated cash flows to fund its operations for at least the next 12 months. The Company, however, is unable to predict with certainty the impact of geopolitical and macroeconomic conditions, including its effect on the global supply chain, inflation and foreign currency exchange rates, will have on its ability to maintain compliance with the debt covenants contained in the credit agreement related to its Credit Facilities (the "Credit Agreement"), including financial covenants regarding the consolidated fixed charge coverage ratio and consolidated senior net leverage ratio. On April 25, 2024, the Company entered into a Third Amendment (the “Amendment”) to the Credit Agreement to update the calculation of Consolidated EBITDA (as defined in the Credit Agreement) to maintain compliance with the debt covenants as of March 31, 2024. Failing to comply with the covenants to the Credit Agreement, as amended, could adversely affect the Company’s ability to finance its future operations or capital needs, withstand a future downturn in its business or the economy in general, engage in business activities, including future opportunities that may be in its interest, and plan for or react to market conditions or otherwise execute its business strategies. The Company’s ability to comply with the covenants and other terms governing the Credit Facilities will depend in part on its future operating performance. In addition, because substantially all of the Company’s assets are pledged as a security under the Credit Facilities, if the Company is not able to cure any default or repay outstanding borrowings, such assets are subject to the risk of foreclosure by the Company’s lenders. Failure to meet the covenant requirements in the future could cause the Company to be in default and the maturity of the related debt could be accelerated and become immediately payable. This may require the Company to obtain waivers or additional amendments to the Credit Agreement in order to maintain compliance and there can be no certainty that any such waiver or amendment will be available, or what the cost of such waiver or amendment, if obtained, would be. If the Company is unable to obtain necessary waivers or amendments and the debt under such credit facility is accelerated, the Company would be required to obtain replacement financing at prevailing market rates, which may not be favorable to the Company. There is no guarantee that the Company would be able to satisfy its obligations if any of its indebtedness is accelerated . Use of Estimates The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosures at the date of the financial statements. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company. A ctual results could differ materially from those estimates. Significant Accounting Policies There have been no material changes in the Company’s significant accounting policies during the nine months ended March 31, 2024, compared to the significant accounting policies described in its Annual Report on Form 10-K for the fiscal year ended June 30, 2023 . Accounting Pronouncements Not Yet Effective In December 2023, the Financial Accounting Standards Board (“FASB”) issued a new accounting standard update (“ASU”) 2023-09 to improve the transparency and usefulness of income tax disclosures. The accounting standard expands disclosures to the entity’s income tax rate reconciliation table and requires cash taxes paid disaggregated by jurisdiction. These changes will be applied on a prospective basis. The update will be effective for annual periods beginning after December 15, 2024. The Company plans to adopt ASU 2023-09 on July 1, 2025. The Company is currently assessing the impact of this update on its consolidated financial statement disclosures. In November 2023, the FASB issued ASU 2023-07 to improve reportable segment disclosures. The ASU is intended to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant expenses. The ASU requires disclosures to include significant segment expenses that are regularly provided to the chief operating decision maker (“CODM”), a description of other segment items by reportable segment, and any additional measures of a segment's profit or loss used by the CODM when deciding how to allocate resources. The ASU also requires all annual disclosures to be disclosed in interim periods. The update is effective for fiscal years beginning after December 15, 2023, with early adoption permitted. The Company plans to adopt ASU 2023-07 on July 1, 2024. The ASU requires retrospective application to all prior periods presented in the financial statements. The Company is currently assessing the timing and impact of adopting the updated provisions.

Revenue

Revenue	9 Months Ended
	Mar. 31, 2024
Revenue from Contract with Customer [Abstract]
Revenue	Note 2. Revenue Contract Balances The timing of revenue recognition, billings, and cash collections results in trade receivables, unbilled receivables, and deferred revenues on the unaudited condensed consolidated balance sheets. The Company may offer longer or extended payment terms of more than one year for qualified customers in some circumstances. At times, revenue recognition occurs before the billing, resulting in an unbilled receivable, which represents a contract asset. The contract asset is a component of accounts receivable and other assets for the current and non-current portions, respectively. When the Company receives advances or deposits from customers before revenue is recognized, this results in a contract liability. It can take two or more years from the time of order to revenue recognition due to the Company’s long sales cycle. Changes in the contract assets and liabilities are as follows (dollars in thousands): Change March 31, June 30, $ % Contract Assets: Unbilled accounts receivable – current (1) $ 14,890 $ 9,847 5,043 51 % Interest receivable – current (2) 325 379 ( 54 ) ( 14 %) Long-term accounts receivable (3) 3,103 4,734 ( 1,631 ) ( 34 %) Interest receivable – non-current (3) 483 673 ( 190 ) ( 28 %) Contract Liabilities: Customer advances 15,392 20,777 ( 5,385 ) ( 26 %) Deferred revenue – current 73,734 72,185 1,549 2 % Deferred revenue – non-current 23,624 27,079 ( 3,455 ) ( 13 %) (1) Included in accounts receivable on the unaudited condensed consolidated balance sheets. (2) Included in prepaid expenses and other current assets on the unaudited condensed consolidated balance sheets. (3) Included in other assets on the unaudited condensed consolidated balance sheets. During the nine months ended March 31, 2024, contract assets changed primarily due to changes in the timing of billings that occurred after revenues were recognized and changes in transactions with payment terms exceeding 12 months. During the nine months ended March 31, 2024, contract liabilities changed due to changes in the timing of revenue recognition as a result of changes in shipping timing, modifications to the transaction price, reduced customer deposits for system sales and for which the warranty was deferred. During the three and nine months ended March 31, 2024, the Company recognized revenue of $ 14.1 million and $ 65.3 million, which was included in the deferred revenue balances at June 30, 2023. During the three and nine months ended March 31, 2023, the Company recognized revenue of $ 17.9 million and $ 73.4 million, which was included in the deferred revenue balances at June 30, 2022. Remaining Performance Obligations Remaining performance obligations represent deferred revenue from open contracts for which performance has already started and the transaction price from executed contracts for which performance has not yet started. Service contracts in general are considered month-to-month contracts. As of March 31, 2024, total remaining performance obligations amounted to $ 959.9 million. Of this total amount, $ 63.8 million related to long-term warranty and non-cancellable post-warranty services, which is the estimated revenue expected to be recognized over the remaining service period and warranty period for systems that have been delivered (the time bands reflect management’s best estimate of when the Company will transfer control to the customer and may change based on timing of shipment, readiness of customers’ facilities for installation, installation requirements, and availability of products). The Company has elected the practical expedient to not disclose the unsatisfied performance obligations of contracts with an original expected duration of one year or less. The following table represents the Company's remaining performance obligations related to long-term warranty and non-cancellable post-warranty services as of March 31, 2024 (in thousands): Fiscal years of revenue recognition 2024 2025 2026 Thereafter Long-term warranty and non-cancellable post-warranty services $ 7,991 $ 28,735 $ 18,712 $ 8,358 For the remaining $ 896.1 million of performance obligations (i.e., open systems sales, upgrades, training and other miscellaneous items), the Company estimates 27 % to 30 % will be recognized in the next 12 months, and the remaining portion will be recognized thereafter. The Company’s historical experience indicates that some of its customers will cancel or renegotiate contracts as economic conditions change or when product offerings change during the long sales cycle. The Company anticipates a portion of its open contracts may never result in revenue recognition primarily due to the long sales cycle and factors outside of its control, including changes to its customers' needs or financial condition, changes in government or health insurance reimbursement policies, or changes to regulatory requirements. Based on historical experience and management's best estimate, approximately 24 % of the Company’s $ 849.6 million open system sales contracts as of March 31, 2024 may never result in revenue. Capitalized Contract Costs As of March 31, 2024 and June 30, 2023, the balance of capitalized costs to obtain a contract was $ 13.6 million and $ 11.0 million, respectively. The Company has classified the capitalized costs to obtain a contract as a component of prepaid expenses and other current assets and other assets with respect to the current and non-current portions of capitalized costs, respectively, on the unaudited condensed consolidated balance sheets. Expenses related to capitalized costs to obtain a contract consisted of the following (in thousands): Three Months Ended Nine Months Ended 2024 2023 2024 2023 Amortization of capitalized contract costs $ 1,297 $ 973 $ 2,940 $ 2,820 Impairment loss on capitalized contracts 34 156 110 556

Supplemental Financial Informat

Supplemental Financial Information	9 Months Ended
	Mar. 31, 2024
Supplemental Financial Information Disclosure [Abstract]
Supplemental Financial Information	Note 3. Supplemental Financial Information Balance Sheet Components Financing receivables A financing receivable is a contractual right to receive money, on demand or on fixed or determinable dates, that is recognized as an asset on the Company’s balance sheets. The Company’s financing receivables, consisting of its accounts receivable with contractual maturities of more than one year are included in other assets on the unaudited condensed consolidated balance sheets. The Company evaluates the credit quality of a customer at contract inception and monitors credit quality over the term of the underlying transactions. The Company performs a credit analysis for all new orders and reviews payment history, current order backlog, financial performance of the customers and other variables that augment or mitigate the inherent credit risk of a particular transaction. Such variables include the underlying value and liquidity of the collateral, the essential use of the equipment, the contract term and the inclusion of credit enhancements, such as guarantees, letters of credit or security deposits. The Company classifies accounts as high risk when it considers the financing receivable to be impaired or when management believes there is a significant near-term risk of non‑payment. The Company performs an assessment each quarter of the allowance for credit losses related to its financing receivables. A summary of the Company’s financing receivables is presented as follows (in thousands): March 31, June 30, Financing receivables $ 4,193 $ 5,854 Allowance for credit losses ( 798 ) ( 798 ) Total, net $ 3,395 $ 5,056 Reported as: Current $ 1,496 $ 2,016 Non-current 1,899 3,040 Total, net $ 3,395 $ 5,056 Inventories Inventories consisted of the following (in thousands): March 31, June 30, Raw materials $ 63,193 $ 62,945 Work-in-process 16,619 17,469 Finished goods 79,754 64,736 Inventories $ 159,566 $ 145,150 The Company's inventories on the unaudited condensed consolidated balance sheets are net of reserves. Prepaid and Other Current Assets Prepaid and other current assets consisted of the following (in thousands): March 31, June 30, Value added tax receivables $ 3,766 $ 12,023 Prepaid commissions 5,637 5,866 Capitalized contract costs 1,834 1,782 Income tax receivable 1,148 495 Other prepaid assets 4,773 5,763 Other current assets 1,885 1,683 Total prepaid and other current assets $ 19,043 $ 27,612 Property and equipment, net Property and equipment, net, consisted of the following (in thousands): March 31, June 30, Machinery and equipment $ 45,286 $ 44,779 Leasehold improvements 31,372 26,641 Computer and office equipment 6,321 7,798 Software 11,269 5,191 Furniture and fixtures 1,641 1,581 Construction in progress 2,330 13,499 98,219 99,489 Less: Accumulated depreciation ( 72,832 ) ( 78,563 ) Property and equipment, net $ 25,387 $ 20,926 At March 31, 2024, software includ es $ 8.1 million in capitalized costs for the completed transition of the Company's new enterprise resource planning system in August 2023. The Company will depreciate the enterprise resource planning system over five years. Depreciation expense related to property and equipment was $ 1.6 million and $ 4.3 million during the three and nine months ended March 31, 2024, respectively, and $ 1.1 million and $ 3.3 million during the three and nine months ended March 31, 2023, respectively. Other Assets Other assets consisted of the following (in thousands): March 31, June 30, Capitalized contract costs $ 11,718 $ 9,244 Long-term accounts receivable 3,103 4,734 Capitalized software costs to be sold 4,011 2,853 Deferred tax asset 833 860 Other long-term assets 2,070 2,416 Total other assets $ 21,735 $ 20,107 Capitalized software costs to be sold were $ 4.0 million and $ 2.9 million as of March 31, 2024 and June 30, 2023, respectively. There was no amortization expense or amounts written down to net realizable value for the capitalized software costs to be sold during the three and nine months ended March 31, 2024, and June 30, 2023. Other Accrued Liabilities Other accrued liabilities consisted of the following (in thousands): March 31, June 30, Value added tax liabilities $ 4,609 $ 12,709 Commissions due to third parties 5,090 10,499 Refunds due to customers 6,838 3,364 Accrued consulting 940 2,599 Accrued royalties 2,366 2,398 Interest payable 1,436 453 Income tax payable 1,910 900 Other liabilities 7,514 5,349 Total other accrued liabilities $ 30,703 $ 38,271 Accumulated Other Comprehensive Income (loss) The changes in accumulated other comprehensive income (loss) are excluded from earnings and reported as a component of stockholders’ equity. The foreign currency translation adjustment results from those subsidiaries not using the U.S. Dollar as their functional currency since the majority of their economic activities are primarily denominated in their applicable local currency. Accordingly, all assets and liabilities related to these operations are translated to the U.S. Dollar at the current exchange rates at the end of each period. Revenues and expenses are translated at average exchange rates in effect during the period. The components of accumulated other comprehensive income (loss) in the stockholders' equity section of the Company’s unaudited condensed consolidated balance sheets are as follows (in thousands): March 31, June 30, Cumulative foreign currency translation adjustment $ ( 4,662 ) $ ( 2,332 ) Defined benefit pension obligation 2,754 2,754 Accumulated other comprehensive income (loss) $ ( 1,908 ) $ 422 Statements of Operations Other expense, net, consisted of the following (in thousands): Three Months Ended Nine Months Ended 2024 2023 2024 2023 Interest expense $ ( 2,884 ) $ ( 2,724 ) $ ( 8,728 ) $ ( 7,630 ) Foreign currency exchange gain (loss) 861 ( 244 ) ( 1,373 ) ( 528 ) Other, net ( 337 ) ( 254 ) ( 292 ) ( 453 ) Total other expense, net $ ( 2,360 ) $ ( 3,222 ) $ ( 10,393 ) $ ( 8,611 )

Leases

Leases	9 Months Ended
	Mar. 31, 2024
Leases [Abstract]
Leases	Note 4. Leases The Company has operating leases for corporate offices and warehouse facilities worldwide. Additionally, the Company leases cars, copy machines and laptops that are considered operating leases. Some of the Company’s leases are non-cancellable operating lease agreements with various expiration dates through June 2035 . As of March 31, 2024, the Company had committed to payments of $ 1.6 million related to operating lease agreement where the lease term had not yet commenced as of March 31, 2024, but is expected to commence during the remainder of calendar year 2024 with a lease term of five years . Certain lease agreements include options to renew or terminate the lease, which are not reasonably certain to be exercised and therefore, are not factored into the determination of lease payments. The following table provides information related to the Company’s operating leases (in thousands): Three Months Ended Nine Months Ended 2024 2023 2024 2023 Operating lease costs (1) $ 2,039 $ 2,354 $ 7,049 $ 7,005 Short-term operating lease costs 98 67 231 298 Cash paid for amounts included in the measurement of lease liabilities 1,987 2,461 7,012 6,904 (1) Excludes e xpenses related to short-term lease operating costs. Operating lease right-of-use assets and operating lease liabilities consisted of the following (in thousands): March 31, June 30, Operating lease right-of-use assets Balance at the beginning of period $ 25,853 $ 16,798 Lease assets added 8,464 17,157 Amortization for the period ( 5,190 ) ( 8,102 ) Balance at the end of period $ 29,127 $ 25,853 Operating lease liabilities Balance at the beginning of period $ 27,753 $ 19,020 Lease liabilities added 10,617 16,834 Repayment and interest accretion ( 4,874 ) ( 8,101 ) Balance at the end of period $ 33,496 $ 27,753 Current portion of operating lease liabilities $ 5,279 $ 4,151 Non-current portion of operating lease liabilities 28,217 23,602 Maturities of operating lease liabilities as of March 31, 2024 are presented in the table below (dollars in thousands): Amount 2024 (remaining three months) $ 1,962 2025 4,987 2026 5,963 2027 5,917 2028 4,805 Thereafter 27,650 Total operating lease payments 51,284 Less: imputed interest ( 17,788 ) Present value of operating lease liabilities $ 33,496 Weighted average remaining lease term (in years) 8.7 Weighted average discount rate 10.0 %

Goodwill and Intangible Assets

Goodwill and Intangible Assets	9 Months Ended
	Mar. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Note 5. Goodwill and Intangible Assets Goodwill Activity related to goodwill consisted of the following (in thousands): March 31, June 30, Balance at the beginning of the period $ 57,681 $ 57,840 Currency translation 1 ( 159 ) Balance at the end of the period $ 57,682 $ 57,681 The Company performed its annual goodwill impairment test in the second quarter of fiscal year 2024 and determined that there was no impairment to goodwill. In the third quarter of fiscal year 2024, t he Company determined that its decline in cash flows and a downward adjustment to the fiscal year 2024 annual guidance constituted triggering events for the impairment of goodwill. The Company performed an interim goodwill impairment test and it determined that there was no impairment to goodwill as of March 31, 2024. The Company will continue to monitor its recorded goodwill for indicators of impairment. Purchased Intangible Assets The Company’s carrying amount of acquired intangible assets, net, consisted of the following (in thousands): March 31, 2024 June 30, 2023 Gross Accumulated Net Gross Accumulated Net Patent license $ 1,000 $ ( 1,000 ) $ - $ 1,000 $ ( 893 ) $ 107 Other intangibles 132 ( 62 ) 70 132 ( 29 ) 103 Total intangible assets $ 1,132 $ ( 1,062 ) $ 70 $ 1,132 $ ( 922 ) $ 210 The Company did not identify any triggering events that would indicate a potential impairment of its definite-lived intangible and long-lived assets as of March 31, 2024. The estimated future amortization expense of acquired intangible assets, net, as of March 31, 2024, is as follows (in thousands): Amount 2024 (remaining three months) $ 11 2025 44 2026 15 Total estimated future amortization expense $ 70

Derivative Financial Instrument

Derivative Financial Instruments	9 Months Ended
	Mar. 31, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Financial Instruments	Note 6. Derivative Financial Instruments The Company utilizes foreign currency forward contracts with reputable financial institutions to manage its exposure of fluctuations in foreign currency exchange rates on certain intercompany balances and foreign currency denominated cash, customer receivables and liabilities. The Company does not use derivative financial instruments for speculative or trading purposes. These forward contracts are not designated as hedging instruments for accounting purposes. Principal hedged currencies primarily include the Japanese Yen, Swiss Franc, and Euro. The periods of these forward contracts range up to approximately three months and the notional amounts are intended to be consistent with changes in the underlying exposures. The notional amount of the Company's outstanding forward currency exchange contracts consisted of the following (in thousands): March 31, June 30, Swiss Franc $ 38,637 $ 26,867 Chinese Yuan 5,310 249 Euro 15,613 17,885 British Pound 1,307 516 Indian Rupee 8,215 3,539 Korean Won 900 — Canadian Dollar 1,400 — Japanese Yen 9,151 12,492 Total outstanding forward currency exchange contracts $ 80,533 $ 61,548 Gains and losses on the Company's foreign currency forward contracts are recorded in Other expense, net, on the Company's unaudited condensed consolidated statements of operations. The following table provides information about the gain or loss associated with the Company’s derivative financial instruments not designated as hedging instruments (in thousands): Three Months Ended Nine Months Ended 2024 2023 2024 2023 Foreign currency exchange gain (loss) on forward contracts $ ( 1,577 ) $ 127 $ ( 1,436 ) $ 888

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Mar. 31, 2024
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 7. Fair Value Measurements Fair value is an exit price representing the amount that would be received to sell an asset or paid to transfer a liability, in the principal or most advantageous market, for the asset or liability, in an orderly transaction between market participants on the measurement date. The fair value hierarchy contains three levels of inputs that may be used to measure fair value, as follows: • Level 1— Unadjusted quoted prices that are available in active markets for the identical assets or liabilities at the measurement date. • Level 2— Other observable inputs available at the measurement date, other than quoted prices included in Level 1, either directly or indirectly, including: quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets in non-active markets; inputs other than quoted prices that are observable for the asset or liability; and inputs that are derived principally from or corroborated by other observable market data. • Level 3— Unobservable inputs that cannot be corroborated by observable market data and require the use of significant management judgment. These values are generally determined using pricing models for which the assumptions utilize management’s estimates of market participant assumptions. Assets and Liabilities That Are Measured at Fair Value As of March 31, 2024, the Company had open currency forward contracts to purchase or sell foreign currencies with a stated or notional value of $ 80.5 million. The fair value of the underlying currency, based upon the March 31, 2024 exchange rate, was $ 80.3 million, which it considers to be a Level 2 fair value measurement. As of June 30, 2023, the Company had open currency forward contracts to purchase or sell foreign currencies with a stated or notional value of $ 61.5 million. The fair value of the underlying currency, based upon the June 30, 2023 exchange rate, was $ 61.2 million, which it considers to be a Level 2 fair value measurement. The Company’s convertible debt is measured on a recurring basis using Level 2 based upon observable inputs. The Company's Revolving Credit Facility and Term Loan Facility (as defined in Note 9) collectively (the “Credit Facilities”) reflect the bank quoted market rates, which the Company considers to be a Level 2 fair value measurement. The Company believes that the carrying value of the Credit Facilities approximates its estimated fair value based on the effective interest rate, compared to the current market rate available to the Company at quarter-end. The table below summarizes the carrying value and estimated fair value of the 3.75 % Convertible Senior Notes due 2026, Term Loan Facility, and the Revolving Credit Facility (in thousands): March 31, June 30, Carrying Fair Carrying Fair 3.75 % Convertible Notes due 2026 $ 98,632 $ 90,712 $ 98,189 $ 98,265 Term Loan Facility 64,862 64,862 69,094 69,094 Revolving Credit Facility 10,000 10,000 10,000 10,000 Total $ 173,494 $ 165,574 $ 177,283 $ 177,359

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 8. Commitments and Contingencies Litigation From time to time, the Company is involved in legal proceedings, including claims, investigations, and inquiries, arising in the ordinary course of its business. The Company records a provision for a loss when it believes that it is both probable that a loss has been incurred and the amount can be reasonably estimated. To the extent there is a reasonable possibility that a loss exceeding amounts already recognized may be incurred and the amount of such additional loss would be material, we will either disclose the estimated additional loss or state that such an estimate cannot be made. Currently, management believes the Company does not have any probable and reasonably estimable material losses related to any current legal proceedings and claims. Although occasional adverse decisions or settlements may occur, management does not believe that an adverse determination with respect to any of these claims would individually, or in the aggregate, materially and adversely affect the Company’s financial condition or operating results. Litigation is inherently unpredictable and is subject to significant uncertainties, some of which are beyond the Company’s control. Should any of these estimates and assumptions change or prove to have been incorrect, the Company could incur significant charges related to legal matters that could have a material impact on its results of operations, financial position and cash flows. Indemnities Under the terms of the Company’s software license agreements with its customers, the Company agrees that in the event the software sold infringes upon any patent, copyright, trademark, or any other proprietary right of a third‑party, it will indemnify its customer licensees against any loss, expense, or liability from any damages that may be awarded against its customer. The Company includes this infringement indemnification in all of its software license agreements and selected managed services arrangements. In the event the customer cannot use the software or service due to infringement and the Company cannot obtain the right to use, replace or modify the license or service in a commercially feasible manner so that it no longer infringes, then the Company may terminate the license and provide the customer a refund of the fees paid by the customer for the infringing license or service. The Company has not recorded any liability associated with this indemnification, as it is not aware of any pending or threatened actions that represent probable losses as of March 31, 2024. The Company enters into standard indemnification agreements with its landlords and all superior mortgagees and their respective directors, officers, agents, and employees in the ordinary course of business. Pursuant to these agreements, the Company will indemnify, hold harmless, and agree to reimburse the indemnified party for losses suffered or incurred by the indemnified party, generally the landlords, in connection with any loss, accident, injury, or damage by any third‑party with respect to the leased facilities. The term of these indemnification agreements is from the commencement of the lease agreements until termination of the lease agreements. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited; however, historically, the Company has not incurred claims or costs to defend lawsuits or settle claims related to these indemnification agreements. The Company has not recorded any liability associated with its indemnification agreements as it is not aware of any pending or threatened actions that represent probable losses as of March 31, 2024. Guarantees As of March 31, 2024 and June 30, 2023, the Company had various bank guarantees totaling $ 1.1 million and $ 1.3 million, respectively, primarily related to bidding processes with customers. Royalty Agreement The Company enters into software license agreements with third parties that require royalty payments for each license used. In connection with such agreements, the Company recorded royalty costs of $ 0.4 million and $ 1.3 million during the three and nine months ended March 31, 2024, respectively, and $ 0.7 million and $ 1.8 million during the three and nine months ended March 31, 2023, respectively, which were recorded in cost of revenue or deferred cost of revenue. The Company had approximately $ 2.4 million and $ 2.4 million in accrued royalty payments as of March 31, 2024, and June 30, 2023, respectively, related to royalty agreements. Restructuring Charges On October 25, 2023, the Company informed affected employees of a cost savings initiative to reduce operating expenses resulting in the elimination of approximately 5.9 percent of the Company’s global workforce. The Company did no t record any restructuring charges during the three months ended March 31, 2024 , and recorded $ 2.6 million in restructuring charges during the nine months ended March 31, 2024. These charges are cash-based and are primarily related to severance expenses and other one-time termination benefits. The Company paid approximat ely $ 0.5 million and $ 2.4 million in cash for the restructuring charges during the three and nine months ended March 31, 2024, respectively. At March 31, 2024 , the Company has a remaining accrual of $ 0.2 million, which is included in accrued compensation on the unaudited condensed consolidated balance sheets, and expects to pay the remaining amounts over the remainder of fiscal year 2024.

Debt

Debt	9 Months Ended
	Mar. 31, 2024
Debt Disclosure [Abstract]
Debt	Note 9. Debt The Company's outstanding debt as of March 31, 2024 and June 30, 2023, is as follows (in thousands): March 31, 2024 June 30, 2023 Principal Amount Unamortized Debt Costs Net Carrying Amount Principal Amount Unamortized Debt Costs Net Carrying Amount 3.75% Convertible Senior Notes due 2026 $ 100,000 $ ( 1,368 ) $ 98,632 $ 100,000 $ ( 1,811 ) $ 98,189 Term Loan Facility 65,500 ( 638 ) 64,862 70,000 ( 906 ) 69,094 Revolving Credit Facility 10,000 — 10,000 10,000 — 10,000 Total debt $ 175,500 $ ( 2,006 ) $ 173,494 $ 180,000 $ ( 2,717 ) $ 177,283 Reported as: Short-term debt $ 7,248 $ 5,721 Long-term debt 166,246 171,562 Total debt $ 173,494 $ 177,283 3.75% Convertible Senior Notes due June 2026 In May 2021, the Company issued $ 100.0 million aggregate principal amount of its 3.75 % Convertible Senior Notes due June 2026 (the “ 3.75 % Convertible Notes due 2026”) under an indenture agreement between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee. As of March 31, 2024 , the if-converted value of its 3.75 % Convertible Notes due 2026 did not exceed the outstanding principal amount. Credit Facilities The Company has a $ 40.0 million revolving credit facility (the “Revolving Credit Facility”) and a five-year $ 80.0 million term loan ( the “Term Loan Facility ”) and together with the Revolving Credit Facility, the “Credit Facilities”). In fiscal year 2024, interest on the borrowings under the Credit Facilities is payable in arrears on the applicable interest payment date, at an annual interest rate of reserve-adjusted, 90-day term Secured Overnight Financing Rate ( subject to a 0.50 % floor) plus a margin between 2.50 % and 3.25 % margin, determined by the Consolidated Senior Net Leverage Ratio (as defined in the Credit Agreement). The weighted average effective interest rate on the Term Loan Facility and Revolving Credit Facility was approximately 8.4 % and 8.6 % respectively, during the nine months ended March 31, 2024. The Credit Agreement requires the Company to pay the lenders an unused commitment fee equal to the average unused portion of the Revolving Credit Facilit y. The Company pays a rate of 0.25 % to 0.40 % per annum of the average unused portion of the Revolving Credit Facility, determined by the Consolidated Senior Net Leverage Ratio (as defined in the Credit Agreement). If all or a portion of the loans under the Term Loan Facility are prepaid, then the Company will be required to pay a fee equal to 1 % of the aggregate amount of the loans so prepaid, subject to certain exceptions. The Credit Agreement contains restrictions and covenants applicable to the Company and its subsidiaries. Among other requirements, the Company may not permit the Fixed Charge Coverage Ratio (as defined in the Credit Agreement) to be less than a certain specified ratio for each fiscal quarter during the term of the Credit Agreement or the consolidated senior net leverage ratio to be greater than a certain specified ratio for each fiscal quarter during the term of the Credit Agreement. On April 25, 2024, the Company entered into the Amendment to update the calculation of Consolidated EBITDA (as defined in the Credit Agreement) to maintain compliance with the debt covenants as of March 31, 2024. A summary of interest expense on the 3.75% Convertible Notes due 2026, the Revolving Credit Facility, and the Term Loan Facility is as follows (in thousands): Three Months Ended Nine Months Ended 2024 2023 2024 2023 Interest expense related to contractual interest coupon $ 2,623 $ 2,472 $ 7,945 $ 6,866 Interest expense related to amortization of debt issuance costs 236 241 711 688 Total $ 2,859 $ 2,713 $ 8,656 $ 7,554

Stock Incentive Plan and Employ

Stock Incentive Plan and Employee Stock Purchase Plan	9 Months Ended
	Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]
Stock Incentive Plan and Employee Stock Purchase Plan	Note 10. Stock Incentive Plan and Employee Stock Purchase Plan The following table presents details of share-based compensation expenses, by functional line item, noted within the Company's operating expenses (in thousands): Three Months Ended Nine Months Ended 2024 2023 2024 2023 Cost of revenue $ 422 $ 263 $ 1,048 $ 1,072 Research and development 413 246 1,094 1,017 Selling and marketing 556 298 1,401 1,242 General and administrative 1,344 752 3,898 4,270 Total share-based compensation $ 2,735 $ 1,559 $ 7,441 $ 7,601 On November 9, 2023, the Company’s stockholders approved amending and restating the Company’s 2016 Equity Incentive Plan to increase the number of shares of the Company’s common stock available for issuance by 5.0 million shares.

Net Income (Loss) Per Common Sh

Net Income (Loss) Per Common Share	9 Months Ended
	Mar. 31, 2024
Earnings Per Share [Abstract]
Net Loss Per Common Share	Note 11. Net Income (Loss) Per Common Share Basic earnings per share is computed based on the weighted average number of shares of common stock outstanding during the period. Diluted earnings per share is computed based on the weighted average number of shares of common stock plus the effect of dilutive potential common shares outstanding during the period. Dilutive potential common shares include outstanding share awards. A reconciliation of the numerator and denominator used in the calculation of basic and diluted net income (loss) per common share is as follows (in thousands, except for per share amounts): Three Months Ended Nine Months Ended 2024 2023 2024 2023 Numerator: Net income (loss) $ ( 6,342 ) $ 599 $ ( 18,932 ) $ ( 6,724 ) Denominator: Weighted average shares outstanding - basic 99,197 95,522 97,838 94,532 Dilutive effect of potential common shares — 1,933 — — Weighted average shares outstanding - diluted 99,197 97,455 97,838 94,532 Basic net income (loss) per share $ ( 0.06 ) $ 0.01 $ ( 0.19 ) $ ( 0.07 ) Diluted net income (loss) per share $ ( 0.06 ) $ 0.01 $ ( 0.19 ) $ ( 0.07 ) Anti-dilutive share-based awards, excluded 14,514 6,495 14,514 14,402 The potentially dilutive shares of the Company’s common stock are excluded from the computation of diluted net income (loss) per share when their effect would have been anti‑dilutive. Additionally, the outstanding 3.75 % Convertible Notes due 2026 are included in the calculation of diluted net loss per share only if their inclusion is dilutive for periods during which the 3.75 % Convertible Notes due 2026 were outstanding. The shares of common stock issuable upon conversion of the outstanding principal amount of the 3.75 % Convertible Notes due 2026 as of three and nine months ended March 31, 2024 and 2023 totaled approximately 17.1 million shares and were not included in the basic and diluted net income (loss) per common share as the effect of adding the shares were anti-dilutive.

Segment Information

Segment Information	9 Months Ended
	Mar. 31, 2024
Segment Reporting [Abstract]
Segment Information	Note 12. Segment Information The Company has one operating and reporting segment (oncology systems group), which develops, manufactures and markets proprietary medical devices used in radiation therapy for the treatment of cancer patients. The Company’s Chief Executive Officer, its Chief Operating Decision Maker, reviews financial information presented on a consolidated basis for purposes of making operating decisions and assessing financial performance. The Company does not assess the performance of its individual product lines on measures of profit or loss, or asset-based metrics, therefore, the information below is presented only for revenues and long-lived tangible assets by geographic area. The Company reports its customer revenues in four geographic regions: the Americas, EIMEA, Asia Pacific and Japan. The Americas region primarily includes the United States, Canada, and Latin America. The EIMEA region includes Europe, India, the Middle East and Africa. The Asia Pacific region consists of Asia, Australia and New Zealand. Disaggregation of Revenues The Company disaggregates its revenues from contracts by geographic region, as the Company believes this best depicts how the nature, amount, timing and uncertainty of revenues and cash flows are affected by economic factors. Revenues attributed to a country or region are based on the shipping address of the Company’s customers. Additionally, the Company typically recognizes revenue at a point in time for product revenue and recognizes revenue over time for service revenue. The following summarizes revenue by geographic region (in thousands): Three Months Ended Nine Months Ended 2024 2023 2024 2023 Americas $ 21,270 $ 34,160 $ 65,569 $ 89,364 EIMEA 37,858 37,983 121,191 114,393 China 19,125 22,165 68,715 57,443 Japan 15,200 16,524 38,440 43,712 Asia Pacific, excluding China 7,679 7,228 18,347 24,401 Total $ 101,132 $ 118,060 $ 312,262 $ 329,313 Disaggregation of Long-Lived Assets Information regarding geographic areas in which the Company has long-lived assets, which consists of property, plant and equipment, net, and operating lease right-of-use assets are as follows (in thousands): March 31, June 30, 2024 2023 Americas $ 46,055 $ 41,569 EIMEA 6,387 3,074 China 1,232 501 Japan 602 1,096 Asia Pacific, excluding China 238 539 Total $ 54,514 $ 46,779

Joint Venture

Joint Venture	9 Months Ended
	Mar. 31, 2024
Equity Method Investments and Joint Ventures [Abstract]
Joint Venture	Note 13. Joint Venture In January 2019, the Company’s wholly-owned subsidiary, Accuray Asia Limited (“Accuray Asia”), entered into an agreement with CNNC High Energy Equipment (Tianjin) Co., Ltd. (the “CIRC Subsidiary”), a wholly-owned subsidiary of China Isotope & Radiation Corporation, to form a joint venture, CNNC Accuray (Tianjin) Medical Technology Co. Ltd. (the “JV”), to manufacture and sell radiation oncology systems in China. As of March 31, 2024 , the Company owned a 49 % interest in the JV, which is reported as an investment in joint venture on the Company’s unaudited condensed consolidated balance sheets. The Company applies the equity method of accounting to its ownership interest in the JV as the Company has the ability to exercise significant influence over the JV but lacks controlling financial interest and is not the primary beneficiary. The Company recognizes the 49 % proportionate share of the JV income (loss) on a one-quarter lag due to the timing of the availability of the JV’s financial records. The Company recognizes revenue on sales to the JV in the current period, eliminating a portion of profit to the extent goods sold have not been sold through by the JV to an end customer at the end of such reporting period. The following table shows the reconciliation between the carrying value of the Company's investment in the JV and its proportional share of the underlying equity in net assets of the JV (in thousands): March 31, June 30, Carrying value of investment in joint venture $ 13,586 $ 15,128 Deferred intra-entity profit margin 7,893 5,737 Equity method goodwill ( 4,720 ) ( 4,720 ) Proportional share of equity investment in joint venture $ 16,759 $ 16,145 As of March 31, 2024, the Company’s carrying value of the investment in the JV was decreased for the Company's proportional share of the JV's currency translation adjustment by $ 0.5 million. As of June 30, 2023, the Company’s carrying value of the investment in the JV for the Company's proportional share of the JV's currency translation adjustment was not material. Summarized financial information of the JV is as follows (in thousands): Three Months Ended Nine Months Ended Statement of Operations Data: 2024 2023 2024 2023 Revenue $ 45,173 $ 36,831 $ 99,485 $ 87,554 Gross profit 7,401 6,931 16,014 15,246 Net income 2,091 4,159 2,098 1,991 Net income attributable to the Company 1,024 2,027 1,028 960 Summarized Balance Sheet Data: As of As of Assets Current assets $ 107,893 $ 88,010 Non-current assets 13,417 17,364 Total assets $ 121,310 $ 105,374 Liabilities and Stockholders' Equity Current liabilities $ 86,554 $ 74,990 Non-current liabilities 134 547 Stockholders' equity 34,622 29,837 Total liabilities and stockholders' equity $ 121,310 $ 105,374 The following table shows the activity of the Company’s net revenue recognized from intra-entity profit margin from sales (in thousands): Three Months Ended Nine Months Ended 2024 2023 2024 2023 Sales recognized from released deferred intra-entity profit margin $ 662 $ 1,071 $ 6,975 $ 7,486 Deferred intra-entity profit margin from sales ( 3,112 ) ( 3,390 ) ( 9,131 ) ( 8,819 ) Net revenue deferred from intra-entity profit margin from sales (1) $ ( 2,450 ) $ ( 2,319 ) $ ( 2,156 ) $ ( 1,333 ) (1) Profit earned by the Company from the JV is eliminated through cost of goods sold until it is realized; such profits would generally be considered realized when the inventory has been sold through to third parties.

Income Tax

Income Tax	9 Months Ended
	Mar. 31, 2024
Income Tax Disclosure [Abstract]
Income Tax	Note 14. Income Tax On a quarterly basis, the Company provides for income taxes based upon an estimated annual effective income tax rate. The Company recognized income tax expense, which were primarily related to foreign taxes, of $ 0.4 million and $ 3.3 million during the three and nine months ended March 31, 2024, respectively, and $ 0.5 million and $ 1.9 million during the three and nine months ended March 31, 2023, respectively. Starting in fiscal year 2019, certain income earned by controlling foreign corporations (“CFCs”) must be included in the gross income of the CFC’s U.S. shareholder. The income required to be included in gross income is referred to as global intangible low tax income (“GILTI”) and is defined under IRC Section 951A as the excess of the shareholder’s net CFC tested income over the net deemed tangible income return. The GILTI inclusion amount is expected to be fully absorbed by net operating losses carryforward and is not expected to cause the Company to be in a U.S. taxable income position for fiscal year 2024. There is no material impact on the Company’s unaudited condensed consolidated financial statements for fiscal year 2024 relating to the change in U.S. tax law that requires capitalization and amortization of research and experimental expenditures incurred after July 1, 2022 which has been fully offset by pre-2018 net operating loss carryforwards. The Company will continue to evaluate the impact of this tax law change on future periods. As of March 31, 2024 , the Company’s gross unrecognized tax benefits were $ 21.6 million, of which $ 21.2 million would not affect income tax expense before consideration of any valuation allowance. The Company does not expect its unrecognized tax benefits to change significantly over the next 12 months . Interest and penalties accrued on unrecognized tax benefits and are recorded as a component of income tax expense.

The Company and its Significa_2

The Company and its Significant Accounting Policies (Policies)	9 Months Ended
	Mar. 31, 2024
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Basis of Presentation	Basis of Presentation The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany transactions and balances have been eliminated in consolidation. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”), pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information and note disclosures have been condensed or omitted pursuant to such rules and regulations. The unaudited condensed consolidated financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair presentation of the periods presented. The results for the three and nine months ended March 31, 2024 are not necessarily indicative of the results to be expected for the fiscal year ending June 30, 2024, or for any other future interim period or fiscal year. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and accompanying notes for the fiscal year ended June 30, 2023 included in the Company’s Annual Report on Form 10-K filed with the SEC on September 7, 2023.
Reclassifications	Reclassifications Certain amounts on the unaudited condensed consolidated statements of cash flows and statements of stockholders' equity in prior periods have been reclassified to conform to current year presentation.
Risks and Uncertainties	Risks and Uncertainties The Company is subject to risks and uncertainties caused, directly or indirectly, by events with significant geopolitical and macroeconomic impacts, including, but not limited to, rising inflation; actions taken to counter inflation, including rising interest rates; foreign currency exchange rate fluctuations; uncertainty and volatility in the banking and financial services sector; tightening credit markets; the effects of the COVID-19 pandemic; geopolitical concerns, such as the Russia-Ukraine and Israel-Hamas conflicts and increasing tension between China and the U.S., including with respect to Taiwan; and other factors that may emerge. In particular, the Company is also continuing to navigate supply chain and inflation challenges, and adverse foreign currency exchange rate fluctuations, all of which continues to be a significant headwind that affects the Company’s results of operations. The Company expects that the business of its customers and its own business will continue to be adversely impacted, directly or indirectly, by these macroeconomic and geopolitical issues. Delays in deliveries and installations as a result of the COVID-19 pandemic and its effects on the global economic environment may continue, to some degree, through the remainder of calendar year 2024, which could have a negative impact on our revenue during such period. In addition, ongoing supply chain challenges and logistics costs, including difficulties in obtaining a sufficient supply of component materials and increased component costs, have adversely affected the Company's gross margins and net income (loss), and the Company’s current expectations are that gross margins and net income (loss) will continue to be adversely affected by increased material costs and freight and logistic expenses through at least the remainder of calendar year 2024, if not longer. In addition, reduced budgets and lower capital deployment priority for radiotherapy equipment, along with longer customer installation timelines, in the United States have negatively impacted our revenue during the third quarter of fiscal 2024, which we expect will continue to have an impact through at least fiscal year 2026. Furthermore, certain parts required for the manufacturing and servicing of the Company's products, such as electronic components, are scarce and could be difficult to source, even at increased prices, if the supplier were adversely affected by macroeconomic and geopolitical issues. If such parts become unavailable to the Company, it would not be able to manufacture or service our products, which would adversely impact revenue, gross margins, and net income (loss). The extent of the ongoing impact of these macroeconomic events on our business, our markets and on global economic activity, however, is uncertain and the related financial impact cannot be reasonably estimated with any certainty at this time. The Company’s past results may not be indicative of its future performance, and historical trends, including conversion of backlog to revenue, income (loss) from operations, net income (loss), net income (loss) per share and cash flows may differ materially. The Company continues to critically review its liquidity and anticipated capital requirements in light of the significant uncertainty created by geopolitical and macroeconomic conditions. Based on the Company’s cash and cash equivalents balance, available debt facilities, current business plan and revenue prospects, the Company believes that it will have sufficient cash resources and anticipated cash flows to fund its operations for at least the next 12 months. The Company, however, is unable to predict with certainty the impact of geopolitical and macroeconomic conditions, including its effect on the global supply chain, inflation and foreign currency exchange rates, will have on its ability to maintain compliance with the debt covenants contained in the credit agreement related to its Credit Facilities (the "Credit Agreement"), including financial covenants regarding the consolidated fixed charge coverage ratio and consolidated senior net leverage ratio. On April 25, 2024, the Company entered into a Third Amendment (the “Amendment”) to the Credit Agreement to update the calculation of Consolidated EBITDA (as defined in the Credit Agreement) to maintain compliance with the debt covenants as of March 31, 2024. Failing to comply with the covenants to the Credit Agreement, as amended, could adversely affect the Company’s ability to finance its future operations or capital needs, withstand a future downturn in its business or the economy in general, engage in business activities, including future opportunities that may be in its interest, and plan for or react to market conditions or otherwise execute its business strategies. The Company’s ability to comply with the covenants and other terms governing the Credit Facilities will depend in part on its future operating performance. In addition, because substantially all of the Company’s assets are pledged as a security under the Credit Facilities, if the Company is not able to cure any default or repay outstanding borrowings, such assets are subject to the risk of foreclosure by the Company’s lenders. Failure to meet the covenant requirements in the future could cause the Company to be in default and the maturity of the related debt could be accelerated and become immediately payable. This may require the Company to obtain waivers or additional amendments to the Credit Agreement in order to maintain compliance and there can be no certainty that any such waiver or amendment will be available, or what the cost of such waiver or amendment, if obtained, would be. If the Company is unable to obtain necessary waivers or amendments and the debt under such credit facility is accelerated, the Company would be required to obtain replacement financing at prevailing market rates, which may not be favorable to the Company. There is no guarantee that the Company would be able to satisfy its obligations if any of its indebtedness is accelerated .
Use of Estimates	Use of Estimates The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosures at the date of the financial statements. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company. A ctual results could differ materially from those estimates.
Significant Accounting Policies	Significant Accounting Policies There have been no material changes in the Company’s significant accounting policies during the nine months ended March 31, 2024, compared to the significant accounting policies described in its Annual Report on Form 10-K for the fiscal year ended June 30, 2023 .
Accounting Pronouncements Not Yet Effective
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Accounting Pronouncements Not Yet Effective	Accounting Pronouncements Not Yet Effective In December 2023, the Financial Accounting Standards Board (“FASB”) issued a new accounting standard update (“ASU”) 2023-09 to improve the transparency and usefulness of income tax disclosures. The accounting standard expands disclosures to the entity’s income tax rate reconciliation table and requires cash taxes paid disaggregated by jurisdiction. These changes will be applied on a prospective basis. The update will be effective for annual periods beginning after December 15, 2024. The Company plans to adopt ASU 2023-09 on July 1, 2025. The Company is currently assessing the impact of this update on its consolidated financial statement disclosures. In November 2023, the FASB issued ASU 2023-07 to improve reportable segment disclosures. The ASU is intended to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant expenses. The ASU requires disclosures to include significant segment expenses that are regularly provided to the chief operating decision maker (“CODM”), a description of other segment items by reportable segment, and any additional measures of a segment's profit or loss used by the CODM when deciding how to allocate resources. The ASU also requires all annual disclosures to be disclosed in interim periods. The update is effective for fiscal years beginning after December 15, 2023, with early adoption permitted. The Company plans to adopt ASU 2023-07 on July 1, 2024. The ASU requires retrospective application to all prior periods presented in the financial statements. The Company is currently assessing the timing and impact of adopting the updated provisions.

Revenue (Tables)

Revenue (Tables)	9 Months Ended
	Mar. 31, 2024
Revenue from Contract with Customer [Abstract]
Summary of Contract with Customer, Asset and Liability	Changes in the contract assets and liabilities are as follows (dollars in thousands): Change March 31, June 30, $ % Contract Assets: Unbilled accounts receivable – current (1) $ 14,890 $ 9,847 5,043 51 % Interest receivable – current (2) 325 379 ( 54 ) ( 14 %) Long-term accounts receivable (3) 3,103 4,734 ( 1,631 ) ( 34 %) Interest receivable – non-current (3) 483 673 ( 190 ) ( 28 %) Contract Liabilities: Customer advances 15,392 20,777 ( 5,385 ) ( 26 %) Deferred revenue – current 73,734 72,185 1,549 2 % Deferred revenue – non-current 23,624 27,079 ( 3,455 ) ( 13 %) (1) Included in accounts receivable on the unaudited condensed consolidated balance sheets. (2) Included in prepaid expenses and other current assets on the unaudited condensed consolidated balance sheets. (3) Included in other assets on the unaudited condensed consolidated balance sheets.
Schedule of Remaining Performance Obligations related to Warranty	The following table represents the Company's remaining performance obligations related to long-term warranty and non-cancellable post-warranty services as of March 31, 2024 (in thousands): Fiscal years of revenue recognition 2024 2025 2026 Thereafter Long-term warranty and non-cancellable post-warranty services $ 7,991 $ 28,735 $ 18,712 $ 8,358
Summary of Expenses Related to Capitalized Costs (Details)	Expenses related to capitalized costs to obtain a contract consisted of the following (in thousands): Three Months Ended Nine Months Ended 2024 2023 2024 2023 Amortization of capitalized contract costs $ 1,297 $ 973 $ 2,940 $ 2,820 Impairment loss on capitalized contracts 34 156 110 556

Supplemental Financial Inform_2

Supplemental Financial Information (Tables)	9 Months Ended
	Mar. 31, 2024
Supplemental Financial Information Disclosure [Abstract]
Schedule of Financing Receivables	A summary of the Company’s financing receivables is presented as follows (in thousands): March 31, June 30, Financing receivables $ 4,193 $ 5,854 Allowance for credit losses ( 798 ) ( 798 ) Total, net $ 3,395 $ 5,056 Reported as: Current $ 1,496 $ 2,016 Non-current 1,899 3,040 Total, net $ 3,395 $ 5,056
Schedule of Inventories	Inventories consisted of the following (in thousands): March 31, June 30, Raw materials $ 63,193 $ 62,945 Work-in-process 16,619 17,469 Finished goods 79,754 64,736 Inventories $ 159,566 $ 145,150
Schedule of Prepaid and Other Current Assets	Prepaid and other current assets consisted of the following (in thousands): March 31, June 30, Value added tax receivables $ 3,766 $ 12,023 Prepaid commissions 5,637 5,866 Capitalized contract costs 1,834 1,782 Income tax receivable 1,148 495 Other prepaid assets 4,773 5,763 Other current assets 1,885 1,683 Total prepaid and other current assets $ 19,043 $ 27,612
Schedule of Property and Equipment, Net	Property and equipment, net, consisted of the following (in thousands): March 31, June 30, Machinery and equipment $ 45,286 $ 44,779 Leasehold improvements 31,372 26,641 Computer and office equipment 6,321 7,798 Software 11,269 5,191 Furniture and fixtures 1,641 1,581 Construction in progress 2,330 13,499 98,219 99,489 Less: Accumulated depreciation ( 72,832 ) ( 78,563 ) Property and equipment, net $ 25,387 $ 20,926
Schedule of Other Assets	Other assets consisted of the following (in thousands): March 31, June 30, Capitalized contract costs $ 11,718 $ 9,244 Long-term accounts receivable 3,103 4,734 Capitalized software costs to be sold 4,011 2,853 Deferred tax asset 833 860 Other long-term assets 2,070 2,416 Total other assets $ 21,735 $ 20,107 Capitalized software costs to be sold were $ 4.0 million and $ 2.9 million as of March 31, 2024 and June 30, 2023, respectively. There was no amortization expense or amounts written down to net realizable value for the capitalized software costs to be sold during the three and nine months ended March 31, 2024, and June 30, 2023.
Schedule of Other Accrued Liabilities	Other accrued liabilities consisted of the following (in thousands): March 31, June 30, Value added tax liabilities $ 4,609 $ 12,709 Commissions due to third parties 5,090 10,499 Refunds due to customers 6,838 3,364 Accrued consulting 940 2,599 Accrued royalties 2,366 2,398 Interest payable 1,436 453 Income tax payable 1,910 900 Other liabilities 7,514 5,349 Total other accrued liabilities $ 30,703 $ 38,271
Schedule of Accumulated Other Comprehensive Income (Loss) in the Stockholders' Equity Section	The components of accumulated other comprehensive income (loss) in the stockholders' equity section of the Company’s unaudited condensed consolidated balance sheets are as follows (in thousands): March 31, June 30, Cumulative foreign currency translation adjustment $ ( 4,662 ) $ ( 2,332 ) Defined benefit pension obligation 2,754 2,754 Accumulated other comprehensive income (loss) $ ( 1,908 ) $ 422
Schedule of Statements of Operations	Other expense, net, consisted of the following (in thousands): Three Months Ended Nine Months Ended 2024 2023 2024 2023 Interest expense $ ( 2,884 ) $ ( 2,724 ) $ ( 8,728 ) $ ( 7,630 ) Foreign currency exchange gain (loss) 861 ( 244 ) ( 1,373 ) ( 528 ) Other, net ( 337 ) ( 254 ) ( 292 ) ( 453 ) Total other expense, net $ ( 2,360 ) $ ( 3,222 ) $ ( 10,393 ) $ ( 8,611 )

Leases (Tables)

Leases (Tables)	9 Months Ended
	Mar. 31, 2024
Leases [Abstract]
Schedule of Operating Leases	The following table provides information related to the Company’s operating leases (in thousands): Three Months Ended Nine Months Ended 2024 2023 2024 2023 Operating lease costs (1) $ 2,039 $ 2,354 $ 7,049 $ 7,005 Short-term operating lease costs 98 67 231 298 Cash paid for amounts included in the measurement of lease liabilities 1,987 2,461 7,012 6,904 (1) Excludes e xpenses related to short-term lease operating costs.
Schedule of Operating Lease Right-of-use Assets and Operating Lease Liabilities	Operating lease right-of-use assets and operating lease liabilities consisted of the following (in thousands): March 31, June 30, Operating lease right-of-use assets Balance at the beginning of period $ 25,853 $ 16,798 Lease assets added 8,464 17,157 Amortization for the period ( 5,190 ) ( 8,102 ) Balance at the end of period $ 29,127 $ 25,853 Operating lease liabilities Balance at the beginning of period $ 27,753 $ 19,020 Lease liabilities added 10,617 16,834 Repayment and interest accretion ( 4,874 ) ( 8,101 ) Balance at the end of period $ 33,496 $ 27,753 Current portion of operating lease liabilities $ 5,279 $ 4,151 Non-current portion of operating lease liabilities 28,217 23,602
Schedule of Maturities of Operating Lease Liabilities	Maturities of operating lease liabilities as of March 31, 2024 are presented in the table below (dollars in thousands): Amount 2024 (remaining three months) $ 1,962 2025 4,987 2026 5,963 2027 5,917 2028 4,805 Thereafter 27,650 Total operating lease payments 51,284 Less: imputed interest ( 17,788 ) Present value of operating lease liabilities $ 33,496 Weighted average remaining lease term (in years) 8.7 Weighted average discount rate 10.0 %

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	9 Months Ended
	Mar. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of goodwill	Activity related to goodwill consisted of the following (in thousands): March 31, June 30, Balance at the beginning of the period $ 57,681 $ 57,840 Currency translation 1 ( 159 ) Balance at the end of the period $ 57,682 $ 57,681
Schedule of carrying amount of acquired intangible assets, net	The Company’s carrying amount of acquired intangible assets, net, consisted of the following (in thousands): March 31, 2024 June 30, 2023 Gross Accumulated Net Gross Accumulated Net Patent license $ 1,000 $ ( 1,000 ) $ - $ 1,000 $ ( 893 ) $ 107 Other intangibles 132 ( 62 ) 70 132 ( 29 ) 103 Total intangible assets $ 1,132 $ ( 1,062 ) $ 70 $ 1,132 $ ( 922 ) $ 210
Schedule of estimated future amortization expense of acquired intangible assets, net	The estimated future amortization expense of acquired intangible assets, net, as of March 31, 2024, is as follows (in thousands): Amount 2024 (remaining three months) $ 11 2025 44 2026 15 Total estimated future amortization expense $ 70

Derivative Financial Instrume_2

Derivative Financial Instruments (Tables)	9 Months Ended
	Mar. 31, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Summary of Outstanding Forward Currency Exchange Contracts	The notional amount of the Company's outstanding forward currency exchange contracts consisted of the following (in thousands): March 31, June 30, Swiss Franc $ 38,637 $ 26,867 Chinese Yuan 5,310 249 Euro 15,613 17,885 British Pound 1,307 516 Indian Rupee 8,215 3,539 Korean Won 900 — Canadian Dollar 1,400 — Japanese Yen 9,151 12,492 Total outstanding forward currency exchange contracts $ 80,533 $ 61,548
Schedule of Gain (loss) Associated With the Company's Derivative Financial Instruments	The following table provides information about the gain or loss associated with the Company’s derivative financial instruments not designated as hedging instruments (in thousands): Three Months Ended Nine Months Ended 2024 2023 2024 2023 Foreign currency exchange gain (loss) on forward contracts $ ( 1,577 ) $ 127 $ ( 1,436 ) $ 888

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Mar. 31, 2024
Fair Value Disclosures [Abstract]
Summary of Carrying Values and Estimated Fair Values of Short-Term and Long-Term Debt	The table below summarizes the carrying value and estimated fair value of the 3.75 % Convertible Senior Notes due 2026, Term Loan Facility, and the Revolving Credit Facility (in thousands): March 31, June 30, Carrying Fair Carrying Fair 3.75 % Convertible Notes due 2026 $ 98,632 $ 90,712 $ 98,189 $ 98,265 Term Loan Facility 64,862 64,862 69,094 69,094 Revolving Credit Facility 10,000 10,000 10,000 10,000 Total $ 173,494 $ 165,574 $ 177,283 $ 177,359

Debt (Tables)

Debt (Tables)	9 Months Ended
	Mar. 31, 2024
Debt Disclosure [Abstract]
Schedule of Carrying Values of all Debt	The Company's outstanding debt as of March 31, 2024 and June 30, 2023, is as follows (in thousands): March 31, 2024 June 30, 2023 Principal Amount Unamortized Debt Costs Net Carrying Amount Principal Amount Unamortized Debt Costs Net Carrying Amount 3.75% Convertible Senior Notes due 2026 $ 100,000 $ ( 1,368 ) $ 98,632 $ 100,000 $ ( 1,811 ) $ 98,189 Term Loan Facility 65,500 ( 638 ) 64,862 70,000 ( 906 ) 69,094 Revolving Credit Facility 10,000 — 10,000 10,000 — 10,000 Total debt $ 175,500 $ ( 2,006 ) $ 173,494 $ 180,000 $ ( 2,717 ) $ 177,283 Reported as: Short-term debt $ 7,248 $ 5,721 Long-term debt 166,246 171,562 Total debt $ 173,494 $ 177,283
Summary of Interest Expense on Notes and the Revolving Credit Facility, and the Term Loan Facility	A summary of interest expense on the 3.75% Convertible Notes due 2026, the Revolving Credit Facility, and the Term Loan Facility is as follows (in thousands): Three Months Ended Nine Months Ended 2024 2023 2024 2023 Interest expense related to contractual interest coupon $ 2,623 $ 2,472 $ 7,945 $ 6,866 Interest expense related to amortization of debt issuance costs 236 241 711 688 Total $ 2,859 $ 2,713 $ 8,656 $ 7,554

Stock Incentive Plan and Empl_2

Stock Incentive Plan and Employee Stock Purchase Plan (Tables)	9 Months Ended
	Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]
Summary of Share-based Compensation Expenses by Functional Line Item Noted Within Company's Operating Expenses	The following table presents details of share-based compensation expenses, by functional line item, noted within the Company's operating expenses (in thousands): Three Months Ended Nine Months Ended 2024 2023 2024 2023 Cost of revenue $ 422 $ 263 $ 1,048 $ 1,072 Research and development 413 246 1,094 1,017 Selling and marketing 556 298 1,401 1,242 General and administrative 1,344 752 3,898 4,270 Total share-based compensation $ 2,735 $ 1,559 $ 7,441 $ 7,601

Net Income (Loss) Per Common _2

Net Income (Loss) Per Common Share (Tables)	9 Months Ended
	Mar. 31, 2024
Earnings Per Share [Abstract]
Schedule of reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per common share	A reconciliation of the numerator and denominator used in the calculation of basic and diluted net income (loss) per common share is as follows (in thousands, except for per share amounts): Three Months Ended Nine Months Ended 2024 2023 2024 2023 Numerator: Net income (loss) $ ( 6,342 ) $ 599 $ ( 18,932 ) $ ( 6,724 ) Denominator: Weighted average shares outstanding - basic 99,197 95,522 97,838 94,532 Dilutive effect of potential common shares — 1,933 — — Weighted average shares outstanding - diluted 99,197 97,455 97,838 94,532 Basic net income (loss) per share $ ( 0.06 ) $ 0.01 $ ( 0.19 ) $ ( 0.07 ) Diluted net income (loss) per share $ ( 0.06 ) $ 0.01 $ ( 0.19 ) $ ( 0.07 ) Anti-dilutive share-based awards, excluded 14,514 6,495 14,514 14,402

Segment Information (Tables)

Segment Information (Tables)	9 Months Ended
	Mar. 31, 2024
Segment Reporting [Abstract]
Summary of Revenue by Geographic Region	The following summarizes revenue by geographic region (in thousands): Three Months Ended Nine Months Ended 2024 2023 2024 2023 Americas $ 21,270 $ 34,160 $ 65,569 $ 89,364 EIMEA 37,858 37,983 121,191 114,393 China 19,125 22,165 68,715 57,443 Japan 15,200 16,524 38,440 43,712 Asia Pacific, excluding China 7,679 7,228 18,347 24,401 Total $ 101,132 $ 118,060 $ 312,262 $ 329,313
Schedule of Geographic Areas in Which the Company has Long-Lived Assets, Property, Plant and Equipment Net, and Operating Lease Right of Use Assets	Information regarding geographic areas in which the Company has long-lived assets, which consists of property, plant and equipment, net, and operating lease right-of-use assets are as follows (in thousands): March 31, June 30, 2024 2023 Americas $ 46,055 $ 41,569 EIMEA 6,387 3,074 China 1,232 501 Japan 602 1,096 Asia Pacific, excluding China 238 539 Total $ 54,514 $ 46,779

Joint Venture (Tables)

Joint Venture (Tables)	9 Months Ended
	Mar. 31, 2024
Equity Method Investments and Joint Ventures [Abstract]
Summary of Reconciliation Between the Carrying Value of Investment and Proportional Share of Underlying Equity in Net Assets of Joint Ventures	The following table shows the reconciliation between the carrying value of the Company's investment in the JV and its proportional share of the underlying equity in net assets of the JV (in thousands): March 31, June 30, Carrying value of investment in joint venture $ 13,586 $ 15,128 Deferred intra-entity profit margin 7,893 5,737 Equity method goodwill ( 4,720 ) ( 4,720 ) Proportional share of equity investment in joint venture $ 16,759 $ 16,145
Summary of Financial Information of Joint Ventures (Operations Data)	Summarized financial information of the JV is as follows (in thousands): Three Months Ended Nine Months Ended Statement of Operations Data: 2024 2023 2024 2023 Revenue $ 45,173 $ 36,831 $ 99,485 $ 87,554 Gross profit 7,401 6,931 16,014 15,246 Net income 2,091 4,159 2,098 1,991 Net income attributable to the Company 1,024 2,027 1,028 960
Summary of Financial Information of Joint Ventures (Balance Sheet Data)	Summarized Balance Sheet Data: As of As of Assets Current assets $ 107,893 $ 88,010 Non-current assets 13,417 17,364 Total assets $ 121,310 $ 105,374 Liabilities and Stockholders' Equity Current liabilities $ 86,554 $ 74,990 Non-current liabilities 134 547 Stockholders' equity 34,622 29,837 Total liabilities and stockholders' equity $ 121,310 $ 105,374
Schedule of Net Revenue Recognized From Intra Entity Profit Margin	The following table shows the activity of the Company’s net revenue recognized from intra-entity profit margin from sales (in thousands): Three Months Ended Nine Months Ended 2024 2023 2024 2023 Sales recognized from released deferred intra-entity profit margin $ 662 $ 1,071 $ 6,975 $ 7,486 Deferred intra-entity profit margin from sales ( 3,112 ) ( 3,390 ) ( 9,131 ) ( 8,819 ) Net revenue deferred from intra-entity profit margin from sales (1) $ ( 2,450 ) $ ( 2,319 ) $ ( 2,156 ) $ ( 1,333 ) (1) Profit earned by the Company from the JV is eliminated through cost of goods sold until it is realized; such profits would generally be considered realized when the inventory has been sold through to third parties.

Revenue - Summary of Contract w

Revenue - Summary of Contract with Customer, Asset and Liability (Details) - USD ($) $ in Thousands		9 Months Ended
		Mar. 31, 2024	Jun. 30, 2023
Contract Assets:
Unbilled accounts receivable - current	[1]	$ 14,890	$ 9,847
Interest receivable - current	[2]	325	379
Long-term accounts receivable	[3]	3,103	4,734
Interest receivable - non-current	[3]	483	673
Contract Liabilities:
Customer advances		15,392	20,777
Deferred revenue – current		73,734	72,185
Deferred revenue – non-current		23,624	$ 27,079
Change in assets, value:
Change in unbilled accounts receivable – current, value	[1]	5,043
Change in interest receivable – current, value	[2]	(54)
Change in long-term accounts receivable, value	[3]	(1,631)
Change in Interest receivable – non-current, value	[3]	(190)
Change in liabilities, value:
Change in customer advances, value		(5,385)
Change in deferred revenue – current, value		1,549
Change in deferred revenue – non-current, value		$ (3,455)
Change in assets, percentage:
Change in unbilled accounts receivable – current, percentage	[1]	51%
Change in interest receivable – current, percentage	[2]	(14.00%)
Change in long-term accounts receivable, percentage	[3]	(34.00%)
Change in Interest receivable – non-current, percentage	[3]	(28.00%)
Change in liabilities, percentage:
Change in customer advances, percentage		(26.00%)
Change in deferred revenue – current, percentage		2%
Change in deferred revenue – non-current, percentage		(13.00%)
[1] Included in accounts receivable on the unaudited condensed consolidated balance sheets. Included in prepaid expenses and other current assets on the unaudited condensed consolidated balance sheets. Included in other assets on the unaudited condensed consolidated balance sheets.

Revenue - Additional Informatio

Revenue - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023	Jun. 30, 2023
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Recognition of deferred revenue	$ 14.1	$ 17.9	$ 65.3	$ 73.4
Remaining performance obligations amount	959.9		$ 959.9
Percentage of changes in operating results on entity's revenue			24%
Capitalized costs to obtain a contract	13.6		$ 13.6		$ 11
Long-term Warranty and Service
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Remaining performance obligations amount	63.8		63.8
Performance Obligations Other Than Warrant
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Remaining performance obligations amount	896.1		896.1
Performance Obligations Service Contracts
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Remaining performance obligations amount	$ 849.6		$ 849.6

Revenue - Schedule of Remaining

Revenue - Schedule of Remaining Performance Obligations related to Warranty (Details) - Long-term Warranty and Service $ in Thousands	Mar. 31, 2024 USD ($)
2024	$ 7,991
2025	28,735
2026	18,712
Thereafter	$ 8,358

Revenue - Additional Informat_2

Revenue - Additional Information (Details1) - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2024-04-01	Mar. 31, 2024
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Remaining performance obligations recognized period	12 months
Minimum
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Remaining performance obligations percentage	27%
Maximum
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Remaining performance obligations percentage	30%

Revenue - Summary of Expenses R

Revenue - Summary of Expenses Related to Capitalized Costs (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Revenue from Contract with Customer [Abstract]
Amortization of capitalized contract costs	$ 1,297	$ 973	$ 2,940	$ 2,820
Impairment loss on capitalized contracts	$ 34	$ 156	$ 110	$ 556

Supplemental Financial Inform_3

Supplemental Financial Information - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023	Jun. 30, 2023
Property and equipment, net
Software capitalized cost	$ 8.1		$ 8.1
Depreciation expense	1.6	$ 1.1	4.3	$ 3.3
Prepaid Expense and Other Assets [Abstract]
Capitalized software costs	$ 4		$ 4		$ 2.9

Supplemental Financial Inform_4

Supplemental Financial Information - Summary of Financing Receivables (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Jun. 30, 2023
Financing receivables
Financing receivables	$ 4,193	$ 5,854
Allowance for credit losses	(798)	(798)
Total, net	3,395	5,056
Current	1,496	2,016
Non-current	$ 1,899	$ 3,040

Supplemental Financial Inform_5

Supplemental Financial Information - Summary of Inventories (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Jun. 30, 2023
Inventory, Net [Abstract]
Raw materials	$ 63,193	$ 62,945
Work-in-process	16,619	17,469
Finished goods	79,754	64,736
Inventories	$ 159,566	$ 145,150

Supplemental Financial Inform_6

Supplemental Financial Information - Schedule of Prepaid and Other Current Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Jun. 30, 2023
Prepaid Expense and Other Assets [Abstract]
Value added tax receivables	$ 3,766	$ 12,023
Prepaid commissions	5,637	5,866
Capitalized contract costs	1,834	1,782
Income tax receivable	1,148	495
Other prepaid assets	4,773	5,763
Other current assets	1,885	1,683
Total prepaid and other current assets	$ 19,043	$ 27,612

Supplemental Financial Inform_7

Supplemental Financial Information - Schedule of Property and Equipment, Net (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Jun. 30, 2023
Property and equipment, net
Property and equipment, gross	$ 98,219	$ 99,489
Less: Accumulated depreciation	(72,832)	(78,563)
Property and equipment, net	25,387	20,926
Machinery and Equipment
Property and equipment, net
Property and equipment, gross	45,286	44,779
Leasehold Improvements
Property and equipment, net
Property and equipment, gross	31,372	26,641
Computer and Office Equipment
Property and equipment, net
Property and equipment, gross	6,321	7,798
Software
Property and equipment, net
Property and equipment, gross	11,269	5,191
Furniture and Fixtures
Property and equipment, net
Property and equipment, gross	1,641	1,581
Construction in Progress
Property and equipment, net
Property and equipment, gross	$ 2,330	$ 13,499

Supplemental Financial Inform_8

Supplemental Financial Information - Schedule of Other Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Jun. 30, 2023
Other Assets [Abstract]
Capitalized contract costs	$ 11,718	$ 9,244
Long-term accounts receivable	3,103	4,734
Capitalized software costs to be sold	4,011	2,853
Deferred tax asset	833	860
Other long-term assets	2,070	2,416
Total other assets	$ 21,735	$ 20,107

Supplemental Financial Inform_9

Supplemental Financial Information - Schedule of Other Accrued Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Jun. 30, 2023
Accrued Liabilities and Other Liabilities [Abstract]
Value added tax liabilities	$ 4,609	$ 12,709
Commissions due to third parties	5,090	10,499
Refunds due to customers	6,838	3,364
Accrued consulting	940	2,599
Accrued royalties	2,366	2,398
Interest payable	1,436	453
Income tax payable	1,910	900
Other liabilities	7,514	5,349
Total other accrued liabilities	$ 30,703	$ 38,271

Supplemental Financial Infor_10

Supplemental Financial Information - Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Jun. 30, 2023
Accumulated Other Comprehensive Income (Loss)
Cumulative foreign currency translation adjustment	$ (4,662)	$ (2,332)
Defined benefit pension obligation	2,754	2,754
Accumulated other comprehensive income (loss)	$ (1,908)	$ 422

Supplemental Financial Infor_11

Supplemental Financial Information - Consolidated Statement Of Operations (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Supplemental Financial Information Disclosure [Abstract]
Interest expense	$ (2,884)	$ (2,724)	$ (8,728)	$ (7,630)
Foreign currency exchange gain (loss)	861	(244)	(1,373)	(528)
Other income (expense), net	(337)	(254)	(292)	(453)
Total other expense, net	$ (2,360)	$ (3,222)	$ (10,393)	$ (8,611)

Leases - Additional Information

Leases - Additional Information (Details) $ in Millions	Mar. 31, 2024 USD ($)
Leases [Abstract]
Operating lease agreement payments	$ 1.6
Lease term	5 years

Leases - Schedule of Operating

Leases - Schedule of Operating Leases (Details) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Leases [Abstract]
Operating lease costs	[1]	$ 2,039	$ 2,354	$ 7,049	$ 7,005
Short-term operating lease costs		98	67	231	298
Cash paid for amounts included in the measurement of lease liabilities		$ 1,987	$ 2,461	$ 7,012	$ 6,904
[1] Excludes e xpenses related to short-term lease operating costs.

Leases - Schedule of Operatin_2

Leases - Schedule of Operating Lease Right-of-use Assets and Operating Lease Liabilities (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Mar. 31, 2024	Jun. 30, 2023
Leases [Abstract]
Balance at the beginning of period-Operating lease right-of-use assets	$ 25,853	$ 16,798
Lease assets added	8,464	17,157
Amortization for the period	(5,190)	(8,102)
Balance at the end of period-Operating lease right-of-use assets	29,127	25,853
Balance at the beginning of period- Operating lease liabilities	27,753	19,020
Lease liabilities added	10,617	16,834
Repayment and interest accretion	(4,874)	(8,101)
Balance at the end of period-Operating lease liabilities	33,496	27,753
Current portion of operating lease liabilities	5,279	4,151
Non-current portion of operating lease liabilities	$ 28,217	$ 23,602

Leases - Schedule of Maturities

Leases - Schedule of Maturities of Operating Lease Liabilities (Details) $ in Thousands	Mar. 31, 2024 USD ($)
Leases [Abstract]
2024 (remaining three months)	$ 1,962
2025	4,987
2026	5,963
2027	5,917
2028	4,805
Thereafter	27,650
Total operating lease payments	51,284
Less: imputed interest	(17,788)
Present value of operating lease liabilities	$ 33,496
Weighted average remaining lease term (in years)	8 years 8 months 12 days
Weighted average discount rate	10%

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Schedule of Goodwill (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Mar. 31, 2024	Jun. 30, 2023
Changes in the carrying amount of goodwill
Balance at the beginning of the period	$ 57,681	$ 57,840
Currency translation	1	(159)
Balance at the end of the period	$ 57,682	$ 57,681

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Additional Information (Details) - USD ($)	3 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Finite Lived Intangible Assets [Line Items]
Impairment of goodwill	$ 0	$ 0

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Schedule of Carrying Amount of Acquired Intangible Assets, Net (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Jun. 30, 2023
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 1,132	$ 1,132
Accumulated Amortization	(1,062)	(922)
Net Amount	70	210
Patent license
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	1,000	1,000
Accumulated Amortization	(1,000)	(893)
Net Amount	0	107
Other Intangible Assets [Member]
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	132	132
Accumulated Amortization	(62)	(29)
Net Amount	$ 70	$ 103

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets - Schedule of Estimated Future Amortization Expense of Acquired Intangible Assets, Net (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Jun. 30, 2023
Estimated future amortization expense of purchased intangible assets
2024 (remaining three months)	$ 11
2025	44
2026	15
Total estimated future amortization expense	$ 70	$ 210

Derivative Financial Instrume_3

Derivative Financial Instruments - Additional Information (Details)	9 Months Ended
	Mar. 31, 2024
Maximum
Length of forward contracts	three months

Derivative Financial Instrume_4

Derivative Financial Instruments - Summary of Outstanding Forward Currency Exchange Contracts (Details) - Forward Currency Exchange Contracts - USD ($)	Mar. 31, 2024	Jun. 30, 2023
Outstanding forward currency exchange contracts	$ 80,533,000	$ 61,548,000
Swiss Franc
Outstanding forward currency exchange contracts	38,637,000	26,867,000
Chinese Yuan
Outstanding forward currency exchange contracts	5,310,000	249,000
Euro
Outstanding forward currency exchange contracts	15,613,000	17,885,000
British Pound
Outstanding forward currency exchange contracts	1,307,000	516,000
Indian Rupee
Outstanding forward currency exchange contracts	8,215,000	3,539,000
Korean Won
Outstanding forward currency exchange contracts	900,000	0
Japanese Yen
Outstanding forward currency exchange contracts	9,151,000	12,492,000
Canadian Dollar
Outstanding forward currency exchange contracts	$ 1,400,000	$ 0

Derivative Financial Instrume_5

Derivative Financial Instruments - Schedule of Gain (Loss) Associated with the Company's Derivative Financial Instruments (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Foreign currency exchange gain (loss) on forward contracts	$ 861	$ (244)	$ (1,373)	$ (528)
Other expense, net | Forward contracts
Foreign currency exchange gain (loss) on forward contracts	$ (1,577)	$ 127	$ (1,436)	$ 888

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) - Forward Currency Exchange Contracts - USD ($)	Mar. 31, 2024	Jun. 30, 2023
Financial assets
Outstanding forward currency exchange contracts	$ 80,533,000	$ 61,548,000
Level 2
Financial assets
Outstanding forward currency exchange contracts	80,500,000	61,500,000
Fair value of currency contract based on exchange rate	$ 80,300,000	$ 61,200,000

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Carrying Value and Estimated Fair Value of all Debt (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Jun. 30, 2023
Carrying Value
Fair value measurement
Long term debt	$ 173,494	$ 177,283
Fair Value
Fair value measurement
Long term debt	165,574	177,359
Non-recurring basis | Carrying Value | Level 2 | 3.75% Convertible Notes Due 2026
Fair value measurement
Long term debt	98,632	98,189
Non-recurring basis | Fair Value | Level 2 | 3.75% Convertible Notes Due 2026
Fair value measurement
Long term debt	90,712	98,265
Term Loan Facility | Non-recurring basis | Carrying Value | Level 2
Fair value measurement
Long term debt	64,862	69,094
Term Loan Facility | Non-recurring basis | Fair Value | Level 2
Fair value measurement
Long term debt	64,862	69,094
Revolving Credit Facility | Non-recurring basis | Carrying Value | Level 2
Fair value measurement
Long term debt	10,000	10,000
Revolving Credit Facility | Non-recurring basis | Fair Value | Level 2
Fair value measurement
Long term debt	$ 10,000	$ 10,000

Fair Value Measurements - Sum_2

Fair Value Measurements - Summary of Carrying Value and Estimated Fair Value of all Debt (Parenthetical) (Details)	Mar. 31, 2024	Dec. 31, 2023	Jun. 30, 2023	Mar. 31, 2023	May 31, 2021
3.75% Convertible Notes Due 2026
Fair value measurement
Interest rate (as a percent)	3.75%	3.75%	3.75%	3.75%	3.75%

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
	Oct. 25, 2023	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023	Jun. 30, 2023
Loss Contingencies [Line Items]
Royalty amount accrued		$ 2,366		$ 2,366		$ 2,398
Accrued benefit		200		200
Restructuring Charges		0		2,600
Cash paid for restructuring charges		500		2,400
License agreement | WARF (Wisconsin Alumni Research Foundation)
Loss Contingencies [Line Items]
Royalty costs		400	$ 700	1,300	$ 1,800
Royalty amount accrued		2,400		2,400		2,400
Financial Guarantee | Various Customers
Loss Contingencies [Line Items]
Bank guarantees		$ 1,100		$ 1,100		$ 1,300
Employee Severance | Financial Guarantee
Loss Contingencies [Line Items]
Workforce affected by cost saving initiative (as a percent)	5.90%

Debt - Schedule of Carrying Val

Debt - Schedule of Carrying Values of All Debt (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Jun. 30, 2023
Debt Instrument [Line Items]
Principal amount of the Notes	$ 175,500	$ 180,000
Unamortized debt costs	(2,006)	(2,717)
Net carrying amount	173,494	177,283
Reported as:
Short-term debt	7,248	5,721
Long-term debt	166,246	171,562
Net carrying amount	173,494	177,283
Revolving Credit Facility
Debt Instrument [Line Items]
Principal amount of the Notes	10,000	10,000
Unamortized debt costs	0	0
Net carrying amount	10,000	10,000
Reported as:
Net carrying amount	10,000	10,000
3.75% Convertible Notes Due 2026
Debt Instrument [Line Items]
Principal amount of the Notes	100,000	100,000
Unamortized debt costs	(1,368)	(1,811)
Net carrying amount	98,632	98,189
Reported as:
Net carrying amount	98,632	98,189
Term Loan Facility Due May 2026
Debt Instrument [Line Items]
Principal amount of the Notes	65,500	70,000
Unamortized debt costs	(638)	(906)
Net carrying amount	64,862	69,094
Reported as:
Net carrying amount	$ 64,862	$ 69,094

Debt - Additional Information (

Debt - Additional Information (Details) - USD ($) $ in Thousands	9 Months Ended
	Mar. 31, 2024	Dec. 31, 2023	Jun. 30, 2023	Mar. 31, 2023	May 31, 2021
Debt Instrument [Line Items]
Principal amount of the Notes	$ 175,500		$ 180,000
Unamortized debt costs	$ 2,006		2,717
Revolving Credit Facility
Debt Instrument [Line Items]
Weighted average effective interest rate	8.60%
Principal amount of the Notes	$ 10,000		10,000
Unamortized debt costs	$ 0		$ 0
Term Loan
Debt Instrument [Line Items]
Weighted average effective interest rate	8.40%
3.75% Convertible Notes Due 2026
Debt Instrument [Line Items]
Aggregate principal amount of debt issued					$ 100,000
Interest rate (as a percent)	3.75%	3.75%	3.75%	3.75%	3.75%
Principal amount of the Notes	$ 100,000		$ 100,000
Unamortized debt costs	1,368		$ 1,811
Senior Secured Credit Agreement | Revolving Credit Facility
Debt Instrument [Line Items]
Credit facility borrowing capacity	$ 40,000
Senior Secured Credit Agreement | Term Loan
Debt Instrument [Line Items]
Term of loan	5 years
Credit facility borrowing capacity	$ 80,000
Senior Secured Credit Agreement | Credit Agreement | If all or Portion of Loans Under New Term Loan Facility are Prepaid
Debt Instrument [Line Items]
Unused commitment fee percentage per annum of average unused portion of the New Revolving Credit Facility	1%
Senior Secured Credit Agreement | 90-day SOFR
Debt Instrument [Line Items]
Interest rate determination basis	90-day term Secured Overnight Financing Rate
Senior Secured Credit Agreement | 90-day SOFR | Floor Rate
Debt Instrument [Line Items]
Variable rate (as a percent)	0.50%
Senior Secured Credit Agreement | Minimum | Credit Agreement | Consolidated Senior Net Leverage Ratio is Greater Than or Equal to 3.00:1.00
Debt Instrument [Line Items]
Unused commitment fee percentage per annum of average unused portion of the New Revolving Credit Facility	0.25%
Senior Secured Credit Agreement | Minimum | 90-day SOFR
Debt Instrument [Line Items]
Variable rate (as a percent)	2.50%
Senior Secured Credit Agreement | Maximum | Credit Agreement | Consolidated Senior Net Leverage Ratio is Greater Than or Equal to 3.00:1.00
Debt Instrument [Line Items]
Unused commitment fee percentage per annum of average unused portion of the New Revolving Credit Facility	0.40%
Senior Secured Credit Agreement | Maximum | 90-day SOFR
Debt Instrument [Line Items]
Variable rate (as a percent)	3.25%

Debt - Summary of Interest Expe

Debt - Summary of Interest Expense on Notes and the Revolving Credit Facility, and the Term Loan Facility (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Debt Disclosure [Abstract]
Interest expense related to contractual interest coupon	$ 2,623	$ 2,472	$ 7,945	$ 6,866
Interest expense related to amortization of debt issuance costs	236	241	711	688
Total	$ 2,859	$ 2,713	$ 8,656	$ 7,554

Stock Incentive Plan and Empl_3

Stock Incentive Plan and Employee Stock Purchase Plan - Summary of Share-Based Compensation Expenses by Functional Line Item Noted Within Company's Operating Expenses (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Share-based compensation expenses
Share-based compensation expense	$ 2,735	$ 1,559	$ 7,441	$ 7,601
Cost of revenue
Share-based compensation expenses
Share-based compensation expense	422	263	1,048	1,072
Research and development
Share-based compensation expenses
Share-based compensation expense	413	246	1,094	1,017
Selling and marketing
Share-based compensation expenses
Share-based compensation expense	556	298	1,401	1,242
General and administrative
Share-based compensation expenses
Share-based compensation expense	$ 1,344	$ 752	$ 3,898	$ 4,270

Stock Incentive Plan and Empl_4

Stock Incentive Plan and Employee Stock Purchase Plan - Additional Information (Details) shares in Millions	Nov. 09, 2023 shares
2016 Equity Incentive Plan
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares of stock authorized	5

Net Income (Loss) Per Common _3

Net Income (Loss) Per Common Share - Schedule of reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per common share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended						9 Months Ended
	Mar. 31, 2024	Dec. 31, 2023	Sep. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Mar. 31, 2024	Mar. 31, 2023
Numerator:
Net Income (Loss)	$ (6,342)	$ (9,621)	$ (2,969)	$ 599	$ (1,874)	$ (5,449)	$ (18,932)	$ (6,724)
Denominator:
Weighted average shares outstanding - basic	99,197			95,522			97,838	94,532
Dilutive effect of potential common shares	0			1,933			0	0
Weighted average shares outstanding - diluted	99,197			97,455			97,838	94,532
Basic net income (loss) per share	$ (0.06)			$ 0.01			$ (0.19)	$ (0.07)
Diluted net income (loss) per share	$ (0.06)			$ 0.01			$ (0.19)	$ (0.07)
Anti-dilutive share-based awards, excluded	14,514			6,495			14,514	14,402

Net Income (Loss) Per Common _4

Net Income (Loss) Per Common Share - Additional Information (Details) - shares shares in Millions	3 Months Ended		9 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Jun. 30, 2023	May 31, 2021
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Common stock not included in the calculation of potentially diluted shares	17.1	17.1	17.1	17.1
3.75% Convertible Notes Due 2026
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Interest rate (as a percent)	3.75%	3.75%	3.75%	3.75%	3.75%	3.75%	3.75%
Convertible debt maturity period	2026	2026	2026	2026

Segment Information - Additiona

Segment Information - Additional Information (Details)	9 Months Ended
	Mar. 31, 2024 Segment
Segment Reporting [Abstract]
Number of operating segments	1

Segment Information - Summary o

Segment Information - Summary of Revenue by Geographic Region (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Segment Information
Total net revenue	$ 101,132	$ 118,060	$ 312,262	$ 329,313
Americas
Segment Information
Total net revenue	21,270	34,160	65,569	89,364
Europe, India, Middle East, and Africa
Segment Information
Total net revenue	37,858	37,983	121,191	114,393
China
Segment Information
Total net revenue	19,125	22,165	68,715	57,443
Japan
Segment Information
Total net revenue	15,200	16,524	38,440	43,712
Asia Pacific, excluding China
Segment Information
Total net revenue	$ 7,679	$ 7,228	$ 18,347	$ 24,401

Segment Information - Schedule

Segment Information - Schedule of Geographic Areas in Which the Company has Long-Lived Assets, Property and Equipment Net and Operating Lease Right of Use Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Jun. 30, 2023
Segment Information
Long lived tangible assets	$ 54,514	$ 46,779
Americas
Segment Information
Long lived tangible assets	46,055	41,569
Europe, India, Middle East, and Africa
Segment Information
Long lived tangible assets	6,387	3,074
China
Segment Information
Long lived tangible assets	1,232	501
Japan
Segment Information
Long lived tangible assets	602	1,096
Asia Pacific, excluding China
Segment Information
Long lived tangible assets	$ 238	$ 539

Joint Venture - Additional Info

Joint Venture - Additional Information (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Mar. 31, 2024	Jun. 30, 2023
Schedule Of Equity Method Investments [Line Items]
Currency translation adjustment	$ 1	$ (159)
Joint venture
Schedule Of Equity Method Investments [Line Items]
Percentage of ownership interest in joint venture	49%
Currency translation adjustment	$ 500
Accuray Asia
Schedule Of Equity Method Investments [Line Items]
Proportion of recognizing joint venture income (loss)	49%

Joint Venture - Summary of Reco

Joint Venture - Summary of Reconciliation Between the Carrying Value of Investment and Proportional Share of Underlying Equity in Net Assets of Joint Ventures (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Jun. 30, 2023	Jun. 30, 2022
Schedule of Equity Method Investments [Line Items]
Equity method goodwill	$ 57,682	$ 57,681	$ 57,840
Joint venture
Schedule of Equity Method Investments [Line Items]
Carrying value of investment in joint venture	13,586	15,128
Deferred intra-entity profit margin	7,893	5,737
Equity method goodwill	(4,720)	(4,720)
Proportional share of equity investment in joint venture	$ 16,759	$ 16,145

Joint Venture - Summary of Fina

Joint Venture - Summary of Financial Information of Joint Ventures (Operations Data) (Details) - USD ($) $ in Thousands	3 Months Ended							9 Months Ended
	Dec. 31, 2024	Mar. 31, 2024	Dec. 31, 2023	Sep. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Dec. 31, 2024	Mar. 31, 2024	Dec. 31, 2023	Mar. 31, 2023
Schedule Of Equity Method Investments [Line Items]
Revenue		$ 101,132			$ 118,060				$ 312,262		$ 329,313
Gross profit		29,074			38,718				104,469		116,282
Net income		$ (6,342)	$ (9,621)	$ (2,969)	$ 599	$ (1,874)	$ (5,449)		$ (18,932)		$ (6,724)
CNNC Accuray (Tianjin) Medical Technology Co. Ltd.
Schedule Of Equity Method Investments [Line Items]
Revenue	$ 45,173		36,831					$ 99,485		$ 87,554
Gross profit	7,401		6,931					16,014		15,246
Net income	2,091		4,159					2,098		1,991
Net income attributable to the Company	$ 1,024		$ 2,027					$ 1,028		$ 960

Joint Venture - Summary of Fi_2

Joint Venture - Summary of Financial Information of Joint Ventures (Balance Sheet Data) (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022
Schedule Of Equity Method Investments [Line Items]
Current assets	$ 313,910			$ 338,033
Total assets	462,527			479,214
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities	198,390			198,637
Stockholder's equity	41,081	$ 47,653	$ 50,944	53,659	$ 54,705	$ 51,745	$ 46,991	$ 53,189
Total liabilities and stockholders' equity	$ 462,527			$ 479,214
Joint venture
Schedule Of Equity Method Investments [Line Items]
Current assets		107,893				88,010
Non current assets		13,417				17,364
Total assets		121,310				105,374
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities		86,554				74,990
Non current liabilities		134				547
Stockholder's equity		34,622				29,837
Total liabilities and stockholders' equity		$ 121,310				$ 105,374

Joint Venture - Schedule of Net

Joint Venture - Schedule of Net Revenue Recognized From Intra Entity Profit Margin (Details) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Schedule of Equity Method Investments [Line Items]
Net revenue deferred from intra-entity profit margin from sales				$ (2,156)	$ (1,333)
Joint venture
Schedule of Equity Method Investments [Line Items]
Sales recognized from released deferred intra-entity profit margin		$ 662	$ 1,071	6,975	7,486
Deferred intra-entity profit margin from sales		(3,112)	(3,390)	(9,131)	(8,819)
Net revenue deferred from intra-entity profit margin from sales	[1]	$ (2,450)	$ (2,319)	$ (2,156)	$ (1,333)
[1] Profit earned by the Company from the JV is eliminated through cost of goods sold until it is realized; such profits would generally be considered realized when the inventory has been sold through to third parties.

Income Tax - Additional Informa

Income Tax - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Income Taxes [Line Items]
Income tax expense	$ 444	$ 522	$ 3,254	$ 1,912
Gross unrecognized tax benefits	21,600		21,600
Unrecognized Tax Benefits that Would Impact Effective Tax Rate	21,200		$ 21,200
Subsequent period within which no material changes in unrecognized tax benefits are expected			12 months
Foreign
Income Taxes [Line Items]
Income tax expense	$ 400	$ 500	$ 3,300	$ 1,900